EP1509213A2 - Acetamides et benzamides utilises dans le traitement d'une dysfonction sexuelle - Google Patents
Acetamides et benzamides utilises dans le traitement d'une dysfonction sexuelleInfo
- Publication number
- EP1509213A2 EP1509213A2 EP03755402A EP03755402A EP1509213A2 EP 1509213 A2 EP1509213 A2 EP 1509213A2 EP 03755402 A EP03755402 A EP 03755402A EP 03755402 A EP03755402 A EP 03755402A EP 1509213 A2 EP1509213 A2 EP 1509213A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- acetamide
- hydrogen
- methyl
- cyano
- pyridinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000001880 Sexual dysfunction Diseases 0.000 title claims abstract description 153
- 231100000872 sexual dysfunction Toxicity 0.000 title claims abstract description 153
- 150000003869 acetamides Chemical class 0.000 title description 4
- 229940054066 benzamide antipsychotics Drugs 0.000 title description 4
- 150000003936 benzamides Chemical class 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 327
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 698
- 239000001257 hydrogen Substances 0.000 claims description 698
- -1 cyano, formyl Chemical group 0.000 claims description 550
- 125000000217 alkyl group Chemical group 0.000 claims description 536
- 125000003118 aryl group Chemical group 0.000 claims description 427
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 383
- 229910052736 halogen Inorganic materials 0.000 claims description 363
- 150000002367 halogens Chemical class 0.000 claims description 363
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 356
- 125000001188 haloalkyl group Chemical group 0.000 claims description 317
- 241000124008 Mammalia Species 0.000 claims description 309
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 248
- 238000000034 method Methods 0.000 claims description 237
- 125000003545 alkoxy group Chemical group 0.000 claims description 231
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 194
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 194
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 189
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 189
- 125000001424 substituent group Chemical group 0.000 claims description 187
- 125000003342 alkenyl group Chemical group 0.000 claims description 151
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 149
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 145
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 135
- 125000000623 heterocyclic group Chemical group 0.000 claims description 134
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 103
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 67
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 45
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 43
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 43
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 43
- 125000004076 pyridyl group Chemical group 0.000 claims description 43
- 125000001544 thienyl group Chemical group 0.000 claims description 43
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 37
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 36
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 36
- 229910052760 oxygen Inorganic materials 0.000 claims description 36
- 125000002541 furyl group Chemical group 0.000 claims description 29
- 125000002883 imidazolyl group Chemical group 0.000 claims description 29
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 29
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 29
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 29
- 150000001408 amides Chemical class 0.000 claims description 28
- 150000002148 esters Chemical class 0.000 claims description 28
- 229940002612 prodrug Drugs 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 28
- 239000000651 prodrug Substances 0.000 claims description 27
- 125000004414 alkyl thio group Chemical group 0.000 claims description 25
- 150000001204 N-oxides Chemical class 0.000 claims description 17
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 14
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 14
- 125000002947 alkylene group Chemical group 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 125000005140 aralkylsulfonyl group Chemical group 0.000 claims description 7
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 7
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 7
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 7
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims description 4
- 239000000674 adrenergic antagonist Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims description 4
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 3
- 201000001881 impotence Diseases 0.000 claims description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 171
- 150000002431 hydrogen Chemical class 0.000 claims 66
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 46
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 18
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 claims 17
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- GPOVHMCNZULUQE-UHFFFAOYSA-N 2-(4-pyridin-2-ylpiperazin-1-yl)-n-[2-[[2-(4-pyridin-2-ylpiperazin-1-yl)acetyl]amino]phenyl]acetamide Chemical compound C=1C=CC=C(NC(=O)CN2CCN(CC2)C=2N=CC=CC=2)C=1NC(=O)CN(CC1)CCN1C1=CC=CC=N1 GPOVHMCNZULUQE-UHFFFAOYSA-N 0.000 claims 2
- WVLDFZRXFKJOAW-UHFFFAOYSA-N 2-(4-pyridin-2-ylpiperazin-1-yl)-n-[4-(trifluoromethyl)phenyl]acetamide Chemical compound C1=CC(C(F)(F)F)=CC=C1NC(=O)CN1CCN(C=2N=CC=CC=2)CC1 WVLDFZRXFKJOAW-UHFFFAOYSA-N 0.000 claims 2
- KVVWKRBUKGFGCM-UHFFFAOYSA-N 2-(4-pyridin-2-ylpiperidin-1-yl)-n-(2,4,6-trifluorophenyl)acetamide Chemical compound FC1=CC(F)=CC(F)=C1NC(=O)CN1CCC(C=2N=CC=CC=2)CC1 KVVWKRBUKGFGCM-UHFFFAOYSA-N 0.000 claims 2
- JDDDXWVTTYEARX-UHFFFAOYSA-N 2-[4-(1-methylimidazol-2-yl)piperidin-1-yl]-n-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCC(CC2)C=2N(C=CN=2)C)=C1 JDDDXWVTTYEARX-UHFFFAOYSA-N 0.000 claims 2
- ZDMQKRKGYGAUEA-UHFFFAOYSA-N 2-[4-(3-chloropyridin-2-yl)piperazin-1-yl]-n-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCN(CC2)C=2C(=CC=CN=2)Cl)=C1 ZDMQKRKGYGAUEA-UHFFFAOYSA-N 0.000 claims 2
- JXFGZKBUXYURNL-UHFFFAOYSA-N 2-[4-(3-cyanopyrazin-2-yl)piperazin-1-yl]-n-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCN(CC2)C=2C(=NC=CN=2)C#N)=C1 JXFGZKBUXYURNL-UHFFFAOYSA-N 0.000 claims 2
- CBFIXSRXOHBONU-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-(1,2,3,4-tetrahydronaphthalen-1-yl)acetamide Chemical compound C1CCC2=CC=CC=C2C1NC(=O)CN(CC1)CCN1C1=NC=CC=C1C#N CBFIXSRXOHBONU-UHFFFAOYSA-N 0.000 claims 2
- VQPWUUNARFLDRC-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-(2,5-dimethylpyrazol-3-yl)acetamide Chemical compound CN1N=C(C)C=C1NC(=O)CN1CCN(C=2C(=CC=CN=2)C#N)CC1 VQPWUUNARFLDRC-UHFFFAOYSA-N 0.000 claims 2
- JUDBZRXMVXMNEJ-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-(2-fluorophenyl)acetamide Chemical compound FC1=CC=CC=C1NC(=O)CN1CCN(C=2C(=CC=CN=2)C#N)CC1 JUDBZRXMVXMNEJ-UHFFFAOYSA-N 0.000 claims 2
- HCLDVVGHVFDLEU-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-(2-methoxyphenyl)acetamide Chemical compound COC1=CC=CC=C1NC(=O)CN1CCN(C=2C(=CC=CN=2)C#N)CC1 HCLDVVGHVFDLEU-UHFFFAOYSA-N 0.000 claims 2
- MTDVHDSILBQXRK-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-(2-methylphenyl)acetamide Chemical compound CC1=CC=CC=C1NC(=O)CN1CCN(C=2C(=CC=CN=2)C#N)CC1 MTDVHDSILBQXRK-UHFFFAOYSA-N 0.000 claims 2
- ZUORJSLRDVQWLD-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-(3,4,5-trimethoxyphenyl)acetamide Chemical compound COC1=C(OC)C(OC)=CC(NC(=O)CN2CCN(CC2)C=2C(=CC=CN=2)C#N)=C1 ZUORJSLRDVQWLD-UHFFFAOYSA-N 0.000 claims 2
- YZQZPWOPHNNABV-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-(3,5-dimethylphenyl)acetamide Chemical compound CC1=CC(C)=CC(NC(=O)CN2CCN(CC2)C=2C(=CC=CN=2)C#N)=C1 YZQZPWOPHNNABV-UHFFFAOYSA-N 0.000 claims 2
- XFGQVKMWAUDYEW-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-(3-fluorophenyl)acetamide Chemical compound FC1=CC=CC(NC(=O)CN2CCN(CC2)C=2C(=CC=CN=2)C#N)=C1 XFGQVKMWAUDYEW-UHFFFAOYSA-N 0.000 claims 2
- PCSZOLGHEITNAT-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCN(CC2)C=2C(=CC=CN=2)C#N)=C1 PCSZOLGHEITNAT-UHFFFAOYSA-N 0.000 claims 2
- YKKGDQPEBLDPAI-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-(4-fluoro-3-methylphenyl)acetamide Chemical compound C1=C(F)C(C)=CC(NC(=O)CN2CCN(CC2)C=2C(=CC=CN=2)C#N)=C1 YKKGDQPEBLDPAI-UHFFFAOYSA-N 0.000 claims 2
- SGCYAVJKGPJKQH-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-(4-methylphenyl)acetamide Chemical compound C1=CC(C)=CC=C1NC(=O)CN1CCN(C=2C(=CC=CN=2)C#N)CC1 SGCYAVJKGPJKQH-UHFFFAOYSA-N 0.000 claims 2
- YXHZKRMCFANDAO-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-[2-(trifluoromethyl)phenyl]acetamide Chemical compound FC(F)(F)C1=CC=CC=C1NC(=O)CN1CCN(C=2C(=CC=CN=2)C#N)CC1 YXHZKRMCFANDAO-UHFFFAOYSA-N 0.000 claims 2
- IIBNUZIBDAHSBQ-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-[2-fluoro-5-(trifluoromethyl)phenyl]acetamide Chemical compound FC1=CC=C(C(F)(F)F)C=C1NC(=O)CN1CCN(C=2C(=CC=CN=2)C#N)CC1 IIBNUZIBDAHSBQ-UHFFFAOYSA-N 0.000 claims 2
- UVKUHASCGHPWNS-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-[3-fluoro-5-(trifluoromethyl)phenyl]acetamide Chemical compound FC(F)(F)C1=CC(F)=CC(NC(=O)CN2CCN(CC2)C=2C(=CC=CN=2)C#N)=C1 UVKUHASCGHPWNS-UHFFFAOYSA-N 0.000 claims 2
- RKKACVQRXZHLQN-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-cyclohexylacetamide Chemical compound C1CCCCC1NC(=O)CN(CC1)CCN1C1=NC=CC=C1C#N RKKACVQRXZHLQN-UHFFFAOYSA-N 0.000 claims 2
- KNNZBHGITINDLP-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-phenylacetamide Chemical compound C=1C=CC=CC=1NC(=O)CN(CC1)CCN1C1=NC=CC=C1C#N KNNZBHGITINDLP-UHFFFAOYSA-N 0.000 claims 2
- YXJHRZJHAQYGQD-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperidin-1-yl]-n-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCC(C=2C(=CC=CN=2)C#N)CC1 YXJHRZJHAQYGQD-UHFFFAOYSA-N 0.000 claims 2
- QGVGDGLZEJEHMD-UHFFFAOYSA-N 2-[4-(5-hydroxypyridin-2-yl)piperidin-1-yl]-n-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCC(CC2)C=2N=CC(O)=CC=2)=C1 QGVGDGLZEJEHMD-UHFFFAOYSA-N 0.000 claims 2
- LPCNHMPHEOEADL-UHFFFAOYSA-N 2-[4-[2-(3-methylanilino)-2-oxoethyl]piperazin-1-yl]pyridine-3-carboxamide Chemical compound CC1=CC=CC(NC(=O)CN2CCN(CC2)C=2C(=CC=CN=2)C(N)=O)=C1 LPCNHMPHEOEADL-UHFFFAOYSA-N 0.000 claims 2
- YHMADWVFJMCEGX-UHFFFAOYSA-N 2-[4-[3-(aminomethyl)pyridin-2-yl]piperazin-1-yl]-n-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCN(CC2)C=2C(=CC=CN=2)CN)=C1 YHMADWVFJMCEGX-UHFFFAOYSA-N 0.000 claims 2
- YSPAVWJSKIUKQL-UHFFFAOYSA-N 2-chloro-n-[[4-(3-cyanopyridin-2-yl)piperazin-1-yl]methyl]benzamide Chemical compound ClC1=CC=CC=C1C(=O)NCN1CCN(C=2C(=CC=CN=2)C#N)CC1 YSPAVWJSKIUKQL-UHFFFAOYSA-N 0.000 claims 2
- YVFAMNPADGNDFV-UHFFFAOYSA-N 3,5-dimethoxy-n-[(4-pyridin-2-ylpiperazin-1-yl)methyl]benzamide Chemical compound COC1=CC(OC)=CC(C(=O)NCN2CCN(CC2)C=2N=CC=CC=2)=C1 YVFAMNPADGNDFV-UHFFFAOYSA-N 0.000 claims 2
- QNUQCOKDWVXAGW-UHFFFAOYSA-N 3,5-dimethoxy-n-[(4-pyridin-2-ylpiperidin-1-yl)methyl]benzamide Chemical compound COC1=CC(OC)=CC(C(=O)NCN2CCC(CC2)C=2N=CC=CC=2)=C1 QNUQCOKDWVXAGW-UHFFFAOYSA-N 0.000 claims 2
- GWEGKFJLEOSMQV-UHFFFAOYSA-N 3,5-dimethyl-n-[(4-pyridin-2-ylpiperidin-1-yl)methyl]benzamide Chemical compound CC1=CC(C)=CC(C(=O)NCN2CCC(CC2)C=2N=CC=CC=2)=C1 GWEGKFJLEOSMQV-UHFFFAOYSA-N 0.000 claims 2
- IZPCAEKTQDLCPU-UHFFFAOYSA-N 3-methyl-n-[2-(4-pyridin-2-ylpiperazin-1-yl)ethyl]benzamide Chemical compound CC1=CC=CC(C(=O)NCCN2CCN(CC2)C=2N=CC=CC=2)=C1 IZPCAEKTQDLCPU-UHFFFAOYSA-N 0.000 claims 2
- JPYOCJRKIVLGKX-INIZCTEOSA-N 3-methyl-n-[[(2s)-2-methyl-4-pyridin-2-ylpiperazin-1-yl]methyl]benzamide Chemical compound C([C@@H]1C)N(C=2N=CC=CC=2)CCN1CNC(=O)C1=CC=CC(C)=C1 JPYOCJRKIVLGKX-INIZCTEOSA-N 0.000 claims 2
- XITPWNNNMTWRKP-UHFFFAOYSA-N 4-fluoro-3-methyl-n-[(4-pyridin-2-ylpiperazin-1-yl)methyl]benzamide Chemical compound C1=C(F)C(C)=CC(C(=O)NCN2CCN(CC2)C=2N=CC=CC=2)=C1 XITPWNNNMTWRKP-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010012374 Depressed mood Diseases 0.000 claims 2
- 206010013654 Drug abuse Diseases 0.000 claims 2
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- ZRHKIXSZVHBHIL-UHFFFAOYSA-N N-(2-fluoro-5-methylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound CC1=CC=C(F)C(NC(=O)CN2CCC(CC2)C=2N=CC=CC=2)=C1 ZRHKIXSZVHBHIL-UHFFFAOYSA-N 0.000 claims 2
- KIFJINLLKCLOQB-UHFFFAOYSA-N N-(3-methylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)propanamide Chemical compound C=1C=CC(C)=CC=1NC(=O)C(C)N(CC1)CCC1C1=CC=CC=N1 KIFJINLLKCLOQB-UHFFFAOYSA-N 0.000 claims 2
- AJLLLRLCDMZMTM-UHFFFAOYSA-N N-(4-fluoro-2-methylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound CC1=CC(F)=CC=C1NC(=O)CN1CCC(C=2N=CC=CC=2)CC1 AJLLLRLCDMZMTM-UHFFFAOYSA-N 0.000 claims 2
- NFQIHBBFAWWAQI-UHFFFAOYSA-N N-(4-fluoro-3-methylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound C1=C(F)C(C)=CC(NC(=O)CN2CCC(CC2)C=2N=CC=CC=2)=C1 NFQIHBBFAWWAQI-UHFFFAOYSA-N 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 2
- ZELZJHWRXDWALG-UHFFFAOYSA-N ethyl 4-[[2-(4-pyridin-2-ylpiperidin-1-yl)acetyl]amino]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1NC(=O)CN1CCC(C=2N=CC=CC=2)CC1 ZELZJHWRXDWALG-UHFFFAOYSA-N 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- ZTZXEXRNSNHUSZ-UHFFFAOYSA-N n-(1-methylbenzimidazol-2-yl)-2-[3-(1,3-thiazol-2-yl)piperidin-1-yl]acetamide Chemical compound N=1C2=CC=CC=C2N(C)C=1NC(=O)CN(C1)CCCC1C1=NC=CS1 ZTZXEXRNSNHUSZ-UHFFFAOYSA-N 0.000 claims 2
- PCNZNIVBYSJFKW-UHFFFAOYSA-N n-(2,3-dichlorophenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)acetamide Chemical compound ClC1=CC=CC(NC(=O)CN2CCN(CC2)C=2N=CC=CC=2)=C1Cl PCNZNIVBYSJFKW-UHFFFAOYSA-N 0.000 claims 2
- WQOXEMYNUDKQQG-UHFFFAOYSA-N n-(2,3-dichlorophenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound ClC1=CC=CC(NC(=O)CN2CCC(CC2)C=2N=CC=CC=2)=C1Cl WQOXEMYNUDKQQG-UHFFFAOYSA-N 0.000 claims 2
- HXWMJCVKQZTZNF-UHFFFAOYSA-N n-(2,4-difluorophenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)acetamide Chemical compound FC1=CC(F)=CC=C1NC(=O)CN1CCN(C=2N=CC=CC=2)CC1 HXWMJCVKQZTZNF-UHFFFAOYSA-N 0.000 claims 2
- ZKUFCBSHURBERN-UHFFFAOYSA-N n-(2,4-difluorophenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound FC1=CC(F)=CC=C1NC(=O)CN1CCC(C=2N=CC=CC=2)CC1 ZKUFCBSHURBERN-UHFFFAOYSA-N 0.000 claims 2
- QSMYJHZYVFPGMQ-UHFFFAOYSA-N n-(2,5-dimethylphenyl)-2-(4-thiophen-2-ylpiperidin-1-yl)acetamide Chemical compound CC1=CC=C(C)C(NC(=O)CN2CCC(CC2)C=2SC=CC=2)=C1 QSMYJHZYVFPGMQ-UHFFFAOYSA-N 0.000 claims 2
- JLGAQXSAVCLCBI-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(C=2N=CC=CC=2)CC1 JLGAQXSAVCLCBI-UHFFFAOYSA-N 0.000 claims 2
- XJOFQVPAGWEIHV-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCC(C=2N=CC=CC=2)CC1 XJOFQVPAGWEIHV-UHFFFAOYSA-N 0.000 claims 2
- ZZJXMZKQVBVTHS-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-(4-thiophen-2-ylpiperidin-1-yl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCC(C=2SC=CC=2)CC1 ZZJXMZKQVBVTHS-UHFFFAOYSA-N 0.000 claims 2
- JJKSMCTVAAPVHQ-UHFFFAOYSA-N n-(2-ethyl-6-methylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound CCC1=CC=CC(C)=C1NC(=O)CN1CCC(C=2N=CC=CC=2)CC1 JJKSMCTVAAPVHQ-UHFFFAOYSA-N 0.000 claims 2
- SLFFKYMTBLWEDA-UHFFFAOYSA-N n-(2-methoxy-6-methylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound COC1=CC=CC(C)=C1NC(=O)CN1CCC(C=2N=CC=CC=2)CC1 SLFFKYMTBLWEDA-UHFFFAOYSA-N 0.000 claims 2
- DGWJMCNSDJHWPO-UHFFFAOYSA-N n-(2-methylphenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)acetamide Chemical compound CC1=CC=CC=C1NC(=O)CN1CCN(C=2N=CC=CC=2)CC1 DGWJMCNSDJHWPO-UHFFFAOYSA-N 0.000 claims 2
- CSVQXWYJXPSYKE-UHFFFAOYSA-N n-(2-methylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound CC1=CC=CC=C1NC(=O)CN1CCC(C=2N=CC=CC=2)CC1 CSVQXWYJXPSYKE-UHFFFAOYSA-N 0.000 claims 2
- WNFUGYBPBGKYLF-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(=O)CN1CCN(C=2N=CC=CC=2)CC1 WNFUGYBPBGKYLF-UHFFFAOYSA-N 0.000 claims 2
- KHTRFZBZNRYFHU-UHFFFAOYSA-N n-(3-bromophenyl)-2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]acetamide Chemical compound BrC1=CC=CC(NC(=O)CN2CCN(CC2)C=2C(=CC=CN=2)C#N)=C1 KHTRFZBZNRYFHU-UHFFFAOYSA-N 0.000 claims 2
- MFFJPWQYNUQOAV-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-2-(4-thiophen-2-ylpiperidin-1-yl)acetamide Chemical compound C1=C(Cl)C(F)=CC=C1NC(=O)CN1CCC(C=2SC=CC=2)CC1 MFFJPWQYNUQOAV-UHFFFAOYSA-N 0.000 claims 2
- RBQPCRFEHLPSQV-UHFFFAOYSA-N n-(3-chlorophenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound ClC1=CC=CC(NC(=O)CN2CCC(CC2)C=2N=CC=CC=2)=C1 RBQPCRFEHLPSQV-UHFFFAOYSA-N 0.000 claims 2
- HZSZCTXGAUHMIW-UHFFFAOYSA-N n-(3-cyanophenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)acetamide Chemical compound C=1C=CC(C#N)=CC=1NC(=O)CN(CC1)CCN1C1=CC=CC=N1 HZSZCTXGAUHMIW-UHFFFAOYSA-N 0.000 claims 2
- NGTMWBFIQJHUJK-UHFFFAOYSA-N n-(3-methylphenyl)-2-(2-methyl-4-pyridin-2-ylpiperazin-1-yl)acetamide Chemical compound CC1CN(C=2N=CC=CC=2)CCN1CC(=O)NC1=CC=CC(C)=C1 NGTMWBFIQJHUJK-UHFFFAOYSA-N 0.000 claims 2
- PNVYVDSCMNEZFD-UHFFFAOYSA-N n-(3-methylphenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)ethanethioamide Chemical compound CC1=CC=CC(NC(=S)CN2CCN(CC2)C=2N=CC=CC=2)=C1 PNVYVDSCMNEZFD-UHFFFAOYSA-N 0.000 claims 2
- NGTMWBFIQJHUJK-INIZCTEOSA-N n-(3-methylphenyl)-2-[(2s)-2-methyl-4-pyridin-2-ylpiperazin-1-yl]acetamide Chemical compound C([C@@H]1C)N(C=2N=CC=CC=2)CCN1CC(=O)NC1=CC=CC(C)=C1 NGTMWBFIQJHUJK-INIZCTEOSA-N 0.000 claims 2
- WUHMIYWQHDIGCM-INIZCTEOSA-N n-(3-methylphenyl)-2-[(2s)-2-methyl-4-pyridin-2-ylpiperazin-1-yl]ethanethioamide Chemical compound C([C@@H]1C)N(C=2N=CC=CC=2)CCN1CC(=S)NC1=CC=CC(C)=C1 WUHMIYWQHDIGCM-INIZCTEOSA-N 0.000 claims 2
- XLJJTSFUSLTSPG-UHFFFAOYSA-N n-(3-methylphenyl)-2-[4-(1,3-thiazol-2-yl)piperazin-1-yl]acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCN(CC2)C=2SC=CN=2)=C1 XLJJTSFUSLTSPG-UHFFFAOYSA-N 0.000 claims 2
- YJDOUUFJTRPKOU-UHFFFAOYSA-N n-(3-methylphenyl)-2-[4-(1,3-thiazol-2-yl)piperidin-1-yl]acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCC(CC2)C=2SC=CN=2)=C1 YJDOUUFJTRPKOU-UHFFFAOYSA-N 0.000 claims 2
- POGXUUJJCZJJOX-UHFFFAOYSA-N n-(3-methylphenyl)-2-[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]acetamide Chemical compound CC(C)OC1=CC=CC=C1N1CCN(CC(=O)NC=2C=C(C)C=CC=2)CC1 POGXUUJJCZJJOX-UHFFFAOYSA-N 0.000 claims 2
- ZLFSCACLYSDYBR-UHFFFAOYSA-N n-(3-methylphenyl)-2-[4-(3-methylpyridin-2-yl)piperazin-1-yl]acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCN(CC2)C=2C(=CC=CN=2)C)=C1 ZLFSCACLYSDYBR-UHFFFAOYSA-N 0.000 claims 2
- TWQLJZRWEXRCOD-UHFFFAOYSA-N n-(3-tert-butylphenyl)-2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]acetamide Chemical compound CC(C)(C)C1=CC=CC(NC(=O)CN2CCN(CC2)C=2C(=CC=CN=2)C#N)=C1 TWQLJZRWEXRCOD-UHFFFAOYSA-N 0.000 claims 2
- XNBYWYILCGRSTN-UHFFFAOYSA-N n-(4-bromophenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound C1=CC(Br)=CC=C1NC(=O)CN1CCC(C=2N=CC=CC=2)CC1 XNBYWYILCGRSTN-UHFFFAOYSA-N 0.000 claims 2
- NHAFVARZNICDHJ-UHFFFAOYSA-N n-(4-chloro-2,6-dimethylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound CC1=CC(Cl)=CC(C)=C1NC(=O)CN1CCC(C=2N=CC=CC=2)CC1 NHAFVARZNICDHJ-UHFFFAOYSA-N 0.000 claims 2
- PYGQQQNCHVQFHA-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)acetamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)CN1CCN(C=2N=CC=CC=2)CC1 PYGQQQNCHVQFHA-UHFFFAOYSA-N 0.000 claims 2
- KIYSXGWRLUGEFE-UHFFFAOYSA-N n-(4-fluorophenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)acetamide Chemical compound C1=CC(F)=CC=C1NC(=O)CN1CCN(C=2N=CC=CC=2)CC1 KIYSXGWRLUGEFE-UHFFFAOYSA-N 0.000 claims 2
- VXBDZZHYKLVAJH-UHFFFAOYSA-N n-(4-fluorophenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound C1=CC(F)=CC=C1NC(=O)CN1CCC(C=2N=CC=CC=2)CC1 VXBDZZHYKLVAJH-UHFFFAOYSA-N 0.000 claims 2
- BNNOSDABJMNSSK-UHFFFAOYSA-N n-(4-iodo-3-methylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound C1=C(I)C(C)=CC(NC(=O)CN2CCC(CC2)C=2N=CC=CC=2)=C1 BNNOSDABJMNSSK-UHFFFAOYSA-N 0.000 claims 2
- FLOCQRKCCCUTMN-UHFFFAOYSA-N n-[(4-pyridin-2-ylpiperazin-1-yl)methyl]cyclohexanecarboxamide Chemical compound C1CCCCC1C(=O)NCN(CC1)CCN1C1=CC=CC=N1 FLOCQRKCCCUTMN-UHFFFAOYSA-N 0.000 claims 2
- FSPFIKAMXJWKSF-UHFFFAOYSA-N n-[(4-pyridin-2-ylpiperidin-1-yl)methyl]-3-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)NCN2CCC(CC2)C=2N=CC=CC=2)=C1 FSPFIKAMXJWKSF-UHFFFAOYSA-N 0.000 claims 2
- GTRHRXBDTXNZOT-UHFFFAOYSA-N n-[[4-(3-cyanopyridin-2-yl)piperazin-1-yl]methyl]-2-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)NCN1CCN(C=2C(=CC=CN=2)C#N)CC1 GTRHRXBDTXNZOT-UHFFFAOYSA-N 0.000 claims 2
- ZPXJQSLZQXQZIP-UHFFFAOYSA-N n-[[4-(3-cyanopyridin-2-yl)piperazin-1-yl]methyl]-2-methylbenzamide Chemical compound CC1=CC=CC=C1C(=O)NCN1CCN(C=2C(=CC=CN=2)C#N)CC1 ZPXJQSLZQXQZIP-UHFFFAOYSA-N 0.000 claims 2
- IKYSPPJOAMUQOA-UHFFFAOYSA-N n-[[4-(3-cyanopyridin-2-yl)piperazin-1-yl]methyl]-3-fluorobenzamide Chemical compound FC1=CC=CC(C(=O)NCN2CCN(CC2)C=2C(=CC=CN=2)C#N)=C1 IKYSPPJOAMUQOA-UHFFFAOYSA-N 0.000 claims 2
- YKPGRQXIMUOTCR-UHFFFAOYSA-N n-[[4-(3-cyanopyridin-2-yl)piperazin-1-yl]methyl]-3-methylbenzamide Chemical compound CC1=CC=CC(C(=O)NCN2CCN(CC2)C=2C(=CC=CN=2)C#N)=C1 YKPGRQXIMUOTCR-UHFFFAOYSA-N 0.000 claims 2
- LQYYCILZRHDHCZ-UHFFFAOYSA-N n-[[4-(3-cyanopyridin-2-yl)piperazin-1-yl]methyl]-4-methylbenzamide Chemical compound C1=CC(C)=CC=C1C(=O)NCN1CCN(C=2C(=CC=CN=2)C#N)CC1 LQYYCILZRHDHCZ-UHFFFAOYSA-N 0.000 claims 2
- HZAFYLLRMUQZKK-UHFFFAOYSA-N n-benzyl-2-(4-pyridin-2-ylpiperazin-1-yl)acetamide Chemical compound C=1C=CC=CC=1CNC(=O)CN(CC1)CCN1C1=CC=CC=N1 HZAFYLLRMUQZKK-UHFFFAOYSA-N 0.000 claims 2
- FVNXUDNXRWMPSG-UHFFFAOYSA-N n-phenyl-2-(4-pyridin-2-ylpiperazin-1-yl)acetamide Chemical compound C=1C=CC=CC=1NC(=O)CN(CC1)CCN1C1=CC=CC=N1 FVNXUDNXRWMPSG-UHFFFAOYSA-N 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- VLYYULUUQDTBHI-UHFFFAOYSA-N 2,3-dibromo-5-methyl-N-[(4-pyridin-2-ylpiperidin-1-yl)methyl]benzamide Chemical compound CC1=CC(Br)=C(Br)C(C(=O)NCN2CCC(CC2)C=2N=CC=CC=2)=C1 VLYYULUUQDTBHI-UHFFFAOYSA-N 0.000 claims 1
- FYQCMFLRBKTTMC-UHFFFAOYSA-N 2,3-dimethyl-n-[(4-pyridin-2-ylpiperazin-1-yl)methyl]benzamide Chemical compound CC1=CC=CC(C(=O)NCN2CCN(CC2)C=2N=CC=CC=2)=C1C FYQCMFLRBKTTMC-UHFFFAOYSA-N 0.000 claims 1
- FAYVDJGQPJSPPC-UHFFFAOYSA-N 2-(4-fluoro-4-phenylpiperidin-1-yl)-n-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCC(F)(CC2)C=2C=CC=CC=2)=C1 FAYVDJGQPJSPPC-UHFFFAOYSA-N 0.000 claims 1
- XOTPCDYNZRWJCJ-UHFFFAOYSA-N 2-(4-pyridin-2-yl-3,6-dihydro-2h-pyridin-1-yl)-n-(2,4,6-trichlorophenyl)acetamide Chemical compound ClC1=CC(Cl)=CC(Cl)=C1NC(=O)CN1CC=C(C=2N=CC=CC=2)CC1 XOTPCDYNZRWJCJ-UHFFFAOYSA-N 0.000 claims 1
- KCWFRYFYEVVIAK-UHFFFAOYSA-N 2-(4-pyridin-2-ylpiperazin-1-yl)-n-[2-(trifluoromethyl)phenyl]acetamide Chemical compound FC(F)(F)C1=CC=CC=C1NC(=O)CN1CCN(C=2N=CC=CC=2)CC1 KCWFRYFYEVVIAK-UHFFFAOYSA-N 0.000 claims 1
- NZKNKSMXZMNRES-UHFFFAOYSA-N 2-(4-pyridin-2-ylpiperazin-1-yl)-n-[4-(trifluoromethoxy)phenyl]acetamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC(=O)CN1CCN(C=2N=CC=CC=2)CC1 NZKNKSMXZMNRES-UHFFFAOYSA-N 0.000 claims 1
- YNIDFKZVSRNLCJ-UHFFFAOYSA-N 2-(4-pyridin-2-ylpiperidin-1-yl)-n-(2,4,6-trichlorophenyl)acetamide Chemical compound ClC1=CC(Cl)=CC(Cl)=C1NC(=O)CN1CCC(C=2N=CC=CC=2)CC1 YNIDFKZVSRNLCJ-UHFFFAOYSA-N 0.000 claims 1
- GAXVGTLPEKYXGX-UHFFFAOYSA-N 2-(4-pyridin-2-ylpiperidin-1-yl)-n-[2-(trifluoromethyl)phenyl]acetamide Chemical compound FC(F)(F)C1=CC=CC=C1NC(=O)CN1CCC(C=2N=CC=CC=2)CC1 GAXVGTLPEKYXGX-UHFFFAOYSA-N 0.000 claims 1
- MQUGXMCMWIABLI-UHFFFAOYSA-N 2-(4-pyridin-2-ylpiperidin-1-yl)-n-[3-(trifluoromethyl)phenyl]acetamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)CN2CCC(CC2)C=2N=CC=CC=2)=C1 MQUGXMCMWIABLI-UHFFFAOYSA-N 0.000 claims 1
- ZQGBUSPAQLIBGW-UHFFFAOYSA-N 2-(4-pyridin-2-ylpiperidin-1-yl)-n-[4-(trifluoromethoxy)phenyl]acetamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC(=O)CN1CCC(C=2N=CC=CC=2)CC1 ZQGBUSPAQLIBGW-UHFFFAOYSA-N 0.000 claims 1
- GUHZEIHOEYHGAC-UHFFFAOYSA-N 2-[4-(1-methylimidazol-2-yl)-3,6-dihydro-2h-pyridin-1-yl]-n-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CC=C(CC2)C=2N(C=CN=2)C)=C1 GUHZEIHOEYHGAC-UHFFFAOYSA-N 0.000 claims 1
- SUMREZUIGGHNSU-UHFFFAOYSA-N 2-[4-(2-aminophenyl)piperazin-1-yl]-n-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCN(CC2)C=2C(=CC=CC=2)N)=C1 SUMREZUIGGHNSU-UHFFFAOYSA-N 0.000 claims 1
- CCBPFOQQHAQIPE-UHFFFAOYSA-N 2-[4-(2-chlorophenyl)piperazin-1-yl]-n-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCN(CC2)C=2C(=CC=CC=2)Cl)=C1 CCBPFOQQHAQIPE-UHFFFAOYSA-N 0.000 claims 1
- IPAGYDFLTXLPDA-UHFFFAOYSA-N 2-[4-(2-cyanophenyl)piperazin-1-yl]-n-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCN(CC2)C=2C(=CC=CC=2)C#N)=C1 IPAGYDFLTXLPDA-UHFFFAOYSA-N 0.000 claims 1
- GZFLEWFOWUOBCD-UHFFFAOYSA-N 2-[4-(2-cyanophenyl)piperazin-1-yl]-n-phenylacetamide Chemical compound C=1C=CC=CC=1NC(=O)CN(CC1)CCN1C1=CC=CC=C1C#N GZFLEWFOWUOBCD-UHFFFAOYSA-N 0.000 claims 1
- OKOHHIAUAXZFKB-UHFFFAOYSA-N 2-[4-(2-ethoxyphenyl)piperazin-1-yl]-n-(3-methylphenyl)acetamide Chemical compound CCOC1=CC=CC=C1N1CCN(CC(=O)NC=2C=C(C)C=CC=2)CC1 OKOHHIAUAXZFKB-UHFFFAOYSA-N 0.000 claims 1
- IFDNVLKWZOADOB-UHFFFAOYSA-N 2-[4-(2-fluorophenyl)piperazin-1-yl]-n-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCN(CC2)C=2C(=CC=CC=2)F)=C1 IFDNVLKWZOADOB-UHFFFAOYSA-N 0.000 claims 1
- FYWPKEHMBJSBIK-UHFFFAOYSA-N 2-[4-(2-fluorophenyl)piperidin-1-yl]-n-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCC(CC2)C=2C(=CC=CC=2)F)=C1 FYWPKEHMBJSBIK-UHFFFAOYSA-N 0.000 claims 1
- QUHCGYKGSDKSOY-UHFFFAOYSA-N 2-[4-(2-hydroxyphenyl)piperazin-1-yl]-n-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCN(CC2)C=2C(=CC=CC=2)O)=C1 QUHCGYKGSDKSOY-UHFFFAOYSA-N 0.000 claims 1
- RPQAZCJWLWPCGS-UHFFFAOYSA-N 2-[4-(2-methoxyphenyl)piperazin-1-yl]-n-(1-methylbenzimidazol-2-yl)acetamide Chemical compound COC1=CC=CC=C1N1CCN(CC(=O)NC=2N(C3=CC=CC=C3N=2)C)CC1 RPQAZCJWLWPCGS-UHFFFAOYSA-N 0.000 claims 1
- FENSXJYDPMBEKM-UHFFFAOYSA-N 2-[4-(2-methoxyphenyl)piperazin-1-yl]-n-(3-methylphenyl)acetamide Chemical compound COC1=CC=CC=C1N1CCN(CC(=O)NC=2C=C(C)C=CC=2)CC1 FENSXJYDPMBEKM-UHFFFAOYSA-N 0.000 claims 1
- WNDADDXKRMDNSK-UHFFFAOYSA-N 2-[4-(2-methoxyphenyl)piperidin-1-yl]-n-(3-methylphenyl)acetamide Chemical compound COC1=CC=CC=C1C1CCN(CC(=O)NC=2C=C(C)C=CC=2)CC1 WNDADDXKRMDNSK-UHFFFAOYSA-N 0.000 claims 1
- MDQNVBDSJKFQJD-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)-3,6-dihydro-2h-pyridin-1-yl]-n-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CC=C(C=2C(=CC=CN=2)C#N)CC1 MDQNVBDSJKFQJD-UHFFFAOYSA-N 0.000 claims 1
- JUBLIYZHZAEGST-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-(2,3,4,5,6-pentafluorophenyl)acetamide Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1NC(=O)CN1CCN(C=2C(=CC=CN=2)C#N)CC1 JUBLIYZHZAEGST-UHFFFAOYSA-N 0.000 claims 1
- LPGFEJVLTAQNQZ-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-(2,3-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCN(CC2)C=2C(=CC=CN=2)C#N)=C1C LPGFEJVLTAQNQZ-UHFFFAOYSA-N 0.000 claims 1
- FOVOKBMMJNYOKB-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-(2,5-dimethylphenyl)acetamide Chemical compound CC1=CC=C(C)C(NC(=O)CN2CCN(CC2)C=2C(=CC=CN=2)C#N)=C1 FOVOKBMMJNYOKB-UHFFFAOYSA-N 0.000 claims 1
- PCFARTSROTWBCZ-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-(2-nitrophenyl)acetamide Chemical compound [O-][N+](=O)C1=CC=CC=C1NC(=O)CN1CCN(C=2C(=CC=CN=2)C#N)CC1 PCFARTSROTWBCZ-UHFFFAOYSA-N 0.000 claims 1
- IWZMNHPJJGVVMW-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-(3-nitrophenyl)acetamide Chemical compound [O-][N+](=O)C1=CC=CC(NC(=O)CN2CCN(CC2)C=2C(=CC=CN=2)C#N)=C1 IWZMNHPJJGVVMW-UHFFFAOYSA-N 0.000 claims 1
- UVERFBJZYABEHX-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-(4-fluorophenyl)acetamide Chemical compound C1=CC(F)=CC=C1NC(=O)CN1CCN(C=2C(=CC=CN=2)C#N)CC1 UVERFBJZYABEHX-UHFFFAOYSA-N 0.000 claims 1
- QPSWTCPZCGYFOK-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-[2-fluoro-3-(trifluoromethyl)phenyl]acetamide Chemical compound C1=CC=C(C(F)(F)F)C(F)=C1NC(=O)CN1CCN(C=2C(=CC=CN=2)C#N)CC1 QPSWTCPZCGYFOK-UHFFFAOYSA-N 0.000 claims 1
- XFHFPJIGECIOGK-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-[4-(trifluoromethyl)phenyl]acetamide Chemical compound C1=CC(C(F)(F)F)=CC=C1NC(=O)CN1CCN(C=2C(=CC=CN=2)C#N)CC1 XFHFPJIGECIOGK-UHFFFAOYSA-N 0.000 claims 1
- SVLRMQOEZHBWIF-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-[4-fluoro-3-(trifluoromethyl)phenyl]acetamide Chemical compound C1=C(C(F)(F)F)C(F)=CC=C1NC(=O)CN1CCN(C=2C(=CC=CN=2)C#N)CC1 SVLRMQOEZHBWIF-UHFFFAOYSA-N 0.000 claims 1
- RWTQCFNLBLQANT-UHFFFAOYSA-N 2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]-n-pyridin-3-ylacetamide Chemical compound C=1C=CN=CC=1NC(=O)CN(CC1)CCN1C1=NC=CC=C1C#N RWTQCFNLBLQANT-UHFFFAOYSA-N 0.000 claims 1
- JTICGVUFQRFTMJ-UHFFFAOYSA-N 2-[4-(3-fluorophenyl)piperidin-1-yl]-n-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCC(CC2)C=2C=C(F)C=CC=2)=C1 JTICGVUFQRFTMJ-UHFFFAOYSA-N 0.000 claims 1
- JTGOGLUALADYLE-UHFFFAOYSA-N 2-[4-(3-hydroxyphenyl)piperazin-1-yl]-n-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCN(CC2)C=2C=C(O)C=CC=2)=C1 JTGOGLUALADYLE-UHFFFAOYSA-N 0.000 claims 1
- RORSBVXAVSCRLX-UHFFFAOYSA-N 2-[4-(4-hydroxyphenyl)piperazin-1-yl]-n-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCN(CC2)C=2C=CC(O)=CC=2)=C1 RORSBVXAVSCRLX-UHFFFAOYSA-N 0.000 claims 1
- IFCOSFZCSXEVGH-UHFFFAOYSA-N 2-methyl-n-[[4-(3-methylpyridin-2-yl)-3,6-dihydro-2h-pyridin-1-yl]methyl]benzamide Chemical compound CC1=CC=CC=C1C(=O)NCN1CC=C(C=2C(=CC=CN=2)C)CC1 IFCOSFZCSXEVGH-UHFFFAOYSA-N 0.000 claims 1
- RCDNNJXDJMFSNX-UHFFFAOYSA-N 3,4-difluoro-n-[(4-pyridin-2-ylpiperidin-1-yl)methyl]benzamide Chemical compound C1=C(F)C(F)=CC=C1C(=O)NCN1CCC(C=2N=CC=CC=2)CC1 RCDNNJXDJMFSNX-UHFFFAOYSA-N 0.000 claims 1
- QDJDUJGEVUNRLB-UHFFFAOYSA-N 3-chloro-n-[(4-pyridin-2-ylpiperidin-1-yl)methyl]benzamide Chemical compound ClC1=CC=CC(C(=O)NCN2CCC(CC2)C=2N=CC=CC=2)=C1 QDJDUJGEVUNRLB-UHFFFAOYSA-N 0.000 claims 1
- LMFZASCXAANSLM-UHFFFAOYSA-N 3-chloro-n-[[4-(2-cyanophenyl)piperazin-1-yl]methyl]benzamide Chemical compound ClC1=CC=CC(C(=O)NCN2CCN(CC2)C=2C(=CC=CC=2)C#N)=C1 LMFZASCXAANSLM-UHFFFAOYSA-N 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- JPYOCJRKIVLGKX-UHFFFAOYSA-N 3-methyl-n-[(2-methyl-4-pyridin-2-ylpiperazin-1-yl)methyl]benzamide Chemical compound CC1CN(C=2N=CC=CC=2)CCN1CNC(=O)C1=CC=CC(C)=C1 JPYOCJRKIVLGKX-UHFFFAOYSA-N 0.000 claims 1
- HJJQPYZNIUSDDO-UHFFFAOYSA-N 3-methyl-n-[(4-phenylpiperazin-1-yl)methyl]benzamide Chemical compound CC1=CC=CC(C(=O)NCN2CCN(CC2)C=2C=CC=CC=2)=C1 HJJQPYZNIUSDDO-UHFFFAOYSA-N 0.000 claims 1
- FSGVMBUBNJSWIG-UHFFFAOYSA-N 3-methyl-n-[(4-pyridin-2-ylpiperazin-1-yl)methyl]benzamide Chemical compound CC1=CC=CC(C(=O)NCN2CCN(CC2)C=2N=CC=CC=2)=C1 FSGVMBUBNJSWIG-UHFFFAOYSA-N 0.000 claims 1
- MJWBNONYVUDZCQ-UHFFFAOYSA-N 3-methyl-n-[(4-pyridin-2-ylpiperidin-1-yl)methyl]benzamide Chemical compound CC1=CC=CC(C(=O)NCN2CCC(CC2)C=2N=CC=CC=2)=C1 MJWBNONYVUDZCQ-UHFFFAOYSA-N 0.000 claims 1
- NHKMIUGDLGNFHU-UHFFFAOYSA-N 3-methyl-n-[(4-pyrimidin-2-ylpiperazin-1-yl)methyl]benzamide Chemical compound CC1=CC=CC(C(=O)NCN2CCN(CC2)C=2N=CC=CN=2)=C1 NHKMIUGDLGNFHU-UHFFFAOYSA-N 0.000 claims 1
- JPYOCJRKIVLGKX-MRXNPFEDSA-N 3-methyl-n-[[(2r)-2-methyl-4-pyridin-2-ylpiperazin-1-yl]methyl]benzamide Chemical compound C([C@H]1C)N(C=2N=CC=CC=2)CCN1CNC(=O)C1=CC=CC(C)=C1 JPYOCJRKIVLGKX-MRXNPFEDSA-N 0.000 claims 1
- ATPINSKUJGBMGW-UHFFFAOYSA-N 3-methyl-n-[[4-(1,3-thiazol-2-yl)piperidin-1-yl]methyl]benzamide Chemical compound CC1=CC=CC(C(=O)NCN2CCC(CC2)C=2SC=CN=2)=C1 ATPINSKUJGBMGW-UHFFFAOYSA-N 0.000 claims 1
- 125000002672 4-bromobenzoyl group Chemical group BrC1=CC=C(C(=O)*)C=C1 0.000 claims 1
- XBMMWZRJWVXOOR-UHFFFAOYSA-N 4-chloro-3-methoxy-N-[(4-pyridin-2-ylpiperidin-1-yl)methyl]benzamide Chemical compound C1=C(Cl)C(OC)=CC(C(=O)NCN2CCC(CC2)C=2N=CC=CC=2)=C1 XBMMWZRJWVXOOR-UHFFFAOYSA-N 0.000 claims 1
- PNUAYJRARXKVQH-UHFFFAOYSA-N 4-chloro-n-[[4-(2-methoxyphenyl)piperazin-1-yl]methyl]benzamide Chemical compound COC1=CC=CC=C1N1CCN(CNC(=O)C=2C=CC(Cl)=CC=2)CC1 PNUAYJRARXKVQH-UHFFFAOYSA-N 0.000 claims 1
- SEPXKWMPEQMTEK-UHFFFAOYSA-N 4-fluoro-3-methyl-n-[(4-pyridin-2-yl-3,6-dihydro-2h-pyridin-1-yl)methyl]benzamide Chemical compound C1=C(F)C(C)=CC(C(=O)NCN2CC=C(CC2)C=2N=CC=CC=2)=C1 SEPXKWMPEQMTEK-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 101100063435 Caenorhabditis elegans din-1 gene Proteins 0.000 claims 1
- BRZWFZLRZGUWRU-UHFFFAOYSA-N N-(3,5-dimethoxyphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound COC1=CC(OC)=CC(NC(=O)CN2CCC(CC2)C=2N=CC=CC=2)=C1 BRZWFZLRZGUWRU-UHFFFAOYSA-N 0.000 claims 1
- WCHUCPNAUXWKPS-UHFFFAOYSA-N N-(3-chloro-2-methylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound CC1=C(Cl)C=CC=C1NC(=O)CN1CCC(C=2N=CC=CC=2)CC1 WCHUCPNAUXWKPS-UHFFFAOYSA-N 0.000 claims 1
- DNULYRGWTFLJQL-UHFFFAOYSA-N N-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-3-methylbenzamide Chemical compound CC1=CC=CC(C(=O)NCN2CCN(CC2)C=2C(=CC=CC=2)C#N)=C1 DNULYRGWTFLJQL-UHFFFAOYSA-N 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 claims 1
- COLWNILBDFLTIK-UHFFFAOYSA-N ethyl 4-[[2-(4-pyridin-2-yl-3,6-dihydro-2h-pyridin-1-yl)acetyl]amino]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1NC(=O)CN1CC=C(C=2N=CC=CC=2)CC1 COLWNILBDFLTIK-UHFFFAOYSA-N 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- PJWMRIAMVDOYEJ-UHFFFAOYSA-N n-(1-adamantyl)-2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13NC(=O)CN(CC1)CCN1C1=NC=CC=C1C#N PJWMRIAMVDOYEJ-UHFFFAOYSA-N 0.000 claims 1
- SLGCUSUEZWLUSU-UHFFFAOYSA-N n-(2,5-dimethylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound CC1=CC=C(C)C(NC(=O)CN2CCC(CC2)C=2N=CC=CC=2)=C1 SLGCUSUEZWLUSU-UHFFFAOYSA-N 0.000 claims 1
- MVVVAKNFQCBZSZ-UHFFFAOYSA-N n-(2,6-diethylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)CN1CCC(C=2N=CC=CC=2)CC1 MVVVAKNFQCBZSZ-UHFFFAOYSA-N 0.000 claims 1
- BTVJEXMGRNQBPG-UHFFFAOYSA-N n-(2-chloro-6-methylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound CC1=CC=CC(Cl)=C1NC(=O)CN1CCC(C=2N=CC=CC=2)CC1 BTVJEXMGRNQBPG-UHFFFAOYSA-N 0.000 claims 1
- YDHNWIPWHNPIFP-UHFFFAOYSA-N n-(2-cyanophenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound C=1C=CC=C(C#N)C=1NC(=O)CN(CC1)CCC1C1=CC=CC=N1 YDHNWIPWHNPIFP-UHFFFAOYSA-N 0.000 claims 1
- IFBJKOSXFBETJA-UHFFFAOYSA-N n-(2-methoxy-6-methylphenyl)-2-(4-pyridin-2-yl-3,6-dihydro-2h-pyridin-1-yl)acetamide Chemical compound COC1=CC=CC(C)=C1NC(=O)CN1CC=C(C=2N=CC=CC=2)CC1 IFBJKOSXFBETJA-UHFFFAOYSA-N 0.000 claims 1
- ISENIMZSGHTLEG-UHFFFAOYSA-N n-(2-methyl-6-propan-2-ylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound CC(C)C1=CC=CC(C)=C1NC(=O)CN1CCC(C=2N=CC=CC=2)CC1 ISENIMZSGHTLEG-UHFFFAOYSA-N 0.000 claims 1
- BHKDQERRPNFJKB-UHFFFAOYSA-N n-(2-methylphenyl)-2-(4-thiophen-2-ylpiperidin-1-yl)acetamide Chemical compound CC1=CC=CC=C1NC(=O)CN1CCC(C=2SC=CC=2)CC1 BHKDQERRPNFJKB-UHFFFAOYSA-N 0.000 claims 1
- VRMMJSNQPSYILY-UHFFFAOYSA-N n-(2-nitrophenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound [O-][N+](=O)C1=CC=CC=C1NC(=O)CN1CCC(C=2N=CC=CC=2)CC1 VRMMJSNQPSYILY-UHFFFAOYSA-N 0.000 claims 1
- NRPUZECQXNYSRH-UHFFFAOYSA-N n-(3,5-dichlorophenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound ClC1=CC(Cl)=CC(NC(=O)CN2CCC(CC2)C=2N=CC=CC=2)=C1 NRPUZECQXNYSRH-UHFFFAOYSA-N 0.000 claims 1
- CRDXGNOVDVFSGF-UHFFFAOYSA-N n-(3-benzylphenyl)-2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]acetamide Chemical compound C=1C=CC(CC=2C=CC=CC=2)=CC=1NC(=O)CN(CC1)CCN1C1=NC=CC=C1C#N CRDXGNOVDVFSGF-UHFFFAOYSA-N 0.000 claims 1
- CRJVKNYKOSXPSX-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound C1=C(Cl)C(F)=CC=C1NC(=O)CN1CCC(C=2N=CC=CC=2)CC1 CRJVKNYKOSXPSX-UHFFFAOYSA-N 0.000 claims 1
- NHMXKUVMKDRZBL-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]acetamide Chemical compound C1=C(Cl)C(F)=CC=C1NC(=O)CN1CCN(C=2C(=CC=CN=2)C#N)CC1 NHMXKUVMKDRZBL-UHFFFAOYSA-N 0.000 claims 1
- BCDIGURKOZSKOV-UHFFFAOYSA-N n-(3-chloro-4-methylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound C1=C(Cl)C(C)=CC=C1NC(=O)CN1CCC(C=2N=CC=CC=2)CC1 BCDIGURKOZSKOV-UHFFFAOYSA-N 0.000 claims 1
- HAKRUZUHJSZYPG-UHFFFAOYSA-N n-(3-chlorophenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)acetamide Chemical compound ClC1=CC=CC(NC(=O)CN2CCN(CC2)C=2N=CC=CC=2)=C1 HAKRUZUHJSZYPG-UHFFFAOYSA-N 0.000 claims 1
- CQPWNUPZWDYRMN-UHFFFAOYSA-N n-(3-cyanophenyl)-2-[4-(2-cyanophenyl)piperazin-1-yl]acetamide Chemical compound C=1C=CC(C#N)=CC=1NC(=O)CN(CC1)CCN1C1=CC=CC=C1C#N CQPWNUPZWDYRMN-UHFFFAOYSA-N 0.000 claims 1
- VHBSZTGJNOCNPQ-UHFFFAOYSA-N n-(3-cyanophenyl)-2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]acetamide Chemical compound C=1C=CC(C#N)=CC=1NC(=O)CN(CC1)CCN1C1=NC=CC=C1C#N VHBSZTGJNOCNPQ-UHFFFAOYSA-N 0.000 claims 1
- HIGCNRYZVHDVLB-UHFFFAOYSA-N n-(3-methylphenyl)-2-(3-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CC(CCC2)C=2N=CC=CC=2)=C1 HIGCNRYZVHDVLB-UHFFFAOYSA-N 0.000 claims 1
- JOODQHUYFDNSQV-UHFFFAOYSA-N n-(3-methylphenyl)-2-(4-phenylpiperazin-1-yl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCN(CC2)C=2C=CC=CC=2)=C1 JOODQHUYFDNSQV-UHFFFAOYSA-N 0.000 claims 1
- ZMEYWYCGMCZGRN-UHFFFAOYSA-N n-(3-methylphenyl)-2-(4-phenylpiperidin-1-yl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCC(CC2)C=2C=CC=CC=2)=C1 ZMEYWYCGMCZGRN-UHFFFAOYSA-N 0.000 claims 1
- AJADIMFRRRXJAI-UHFFFAOYSA-N n-(3-methylphenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCN(CC2)C=2N=CC=CC=2)=C1 AJADIMFRRRXJAI-UHFFFAOYSA-N 0.000 claims 1
- VRLIMTLGQLFQSQ-UHFFFAOYSA-N n-(3-methylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)ethanethioamide Chemical compound CC1=CC=CC(NC(=S)CN2CCC(CC2)C=2N=CC=CC=2)=C1 VRLIMTLGQLFQSQ-UHFFFAOYSA-N 0.000 claims 1
- FAUOIWKXVZMERY-UHFFFAOYSA-N n-(3-methylphenyl)-2-(4-pyrimidin-2-ylpiperazin-1-yl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCN(CC2)C=2N=CC=CN=2)=C1 FAUOIWKXVZMERY-UHFFFAOYSA-N 0.000 claims 1
- CEBFDWPSTPEIIR-UHFFFAOYSA-N n-(3-methylphenyl)-2-(4-thiophen-2-yl-3,6-dihydro-2h-pyridin-1-yl)acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CC=C(CC2)C=2SC=CC=2)=C1 CEBFDWPSTPEIIR-UHFFFAOYSA-N 0.000 claims 1
- NGTMWBFIQJHUJK-MRXNPFEDSA-N n-(3-methylphenyl)-2-[(2r)-2-methyl-4-pyridin-2-ylpiperazin-1-yl]acetamide Chemical compound C([C@H]1C)N(C=2N=CC=CC=2)CCN1CC(=O)NC1=CC=CC(C)=C1 NGTMWBFIQJHUJK-MRXNPFEDSA-N 0.000 claims 1
- LYFIGJWATAQOLM-UHFFFAOYSA-N n-(3-methylphenyl)-2-[4-(2-methylphenyl)piperazin-1-yl]acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCN(CC2)C=2C(=CC=CC=2)C)=C1 LYFIGJWATAQOLM-UHFFFAOYSA-N 0.000 claims 1
- NHQAFLBBFNUIGF-UHFFFAOYSA-N n-(3-methylphenyl)-2-[4-(2-methylphenyl)piperidin-1-yl]acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCC(CC2)C=2C(=CC=CC=2)C)=C1 NHQAFLBBFNUIGF-UHFFFAOYSA-N 0.000 claims 1
- FAEHWLLGUILYGQ-UHFFFAOYSA-N n-(3-methylphenyl)-2-[4-(2-methylsulfanylphenyl)piperazin-1-yl]acetamide Chemical compound CSC1=CC=CC=C1N1CCN(CC(=O)NC=2C=C(C)C=CC=2)CC1 FAEHWLLGUILYGQ-UHFFFAOYSA-N 0.000 claims 1
- RRVDOMVZMZTBRM-UHFFFAOYSA-N n-(3-methylphenyl)-2-[4-(3-nitropyridin-2-yl)piperazin-1-yl]acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCN(CC2)C=2C(=CC=CN=2)[N+]([O-])=O)=C1 RRVDOMVZMZTBRM-UHFFFAOYSA-N 0.000 claims 1
- ZMBBHVKBEBCTFF-UHFFFAOYSA-N n-(3-methylphenyl)-2-[4-[3-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]acetamide Chemical compound CC1=CC=CC(NC(=O)CN2CCN(CC2)C=2C(=CC=CN=2)C(F)(F)F)=C1 ZMBBHVKBEBCTFF-UHFFFAOYSA-N 0.000 claims 1
- QJLPMRHBEPBBBS-UHFFFAOYSA-N n-(3-nitrophenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound [O-][N+](=O)C1=CC=CC(NC(=O)CN2CCC(CC2)C=2N=CC=CC=2)=C1 QJLPMRHBEPBBBS-UHFFFAOYSA-N 0.000 claims 1
- JMHZHIGCOITGSS-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(4-pyridin-2-yl-3,6-dihydro-2h-pyridin-1-yl)acetamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)CN1CC=C(C=2N=CC=CC=2)CC1 JMHZHIGCOITGSS-UHFFFAOYSA-N 0.000 claims 1
- XRVINGCSCYNIEJ-UHFFFAOYSA-N n-(4-fluoro-2-methylphenyl)-2-(4-pyridin-2-yl-3,6-dihydro-2h-pyridin-1-yl)acetamide Chemical compound CC1=CC(F)=CC=C1NC(=O)CN1CC=C(C=2N=CC=CC=2)CC1 XRVINGCSCYNIEJ-UHFFFAOYSA-N 0.000 claims 1
- VSOWGWJTGVPBBH-UHFFFAOYSA-N n-(4-methylphenyl)-2-(4-pyridin-2-yl-3,6-dihydro-2h-pyridin-1-yl)acetamide Chemical compound C1=CC(C)=CC=C1NC(=O)CN1CC=C(C=2N=CC=CC=2)CC1 VSOWGWJTGVPBBH-UHFFFAOYSA-N 0.000 claims 1
- YRADWFZJMGLQHV-UHFFFAOYSA-N n-(4-methylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide Chemical compound C1=CC(C)=CC=C1NC(=O)CN1CCC(C=2N=CC=CC=2)CC1 YRADWFZJMGLQHV-UHFFFAOYSA-N 0.000 claims 1
- ZJZXXYNLCDKMKN-UHFFFAOYSA-N n-[(4-pyridin-2-yl-3,6-dihydro-2h-pyridin-1-yl)methyl]cyclohexanecarboxamide Chemical compound C1CCCCC1C(=O)NCN(CC=1)CCC=1C1=CC=CC=N1 ZJZXXYNLCDKMKN-UHFFFAOYSA-N 0.000 claims 1
- JLWQYIGAWFXMRT-UHFFFAOYSA-N n-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)NCN2CCN(CC2)C=2N=CC=CC=2)=C1 JLWQYIGAWFXMRT-UHFFFAOYSA-N 0.000 claims 1
- IBNJEPUNXZMNGU-UHFFFAOYSA-N n-[(4-pyridin-2-ylpiperazin-1-yl)methyl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NCN(CC1)CCN1C1=CC=CC=N1 IBNJEPUNXZMNGU-UHFFFAOYSA-N 0.000 claims 1
- PGBKQYRNRYVCCD-UHFFFAOYSA-N n-[(4-pyridin-2-ylpiperidin-1-yl)methyl]cyclohexanecarboxamide Chemical compound C1CCCCC1C(=O)NCN(CC1)CCC1C1=CC=CC=N1 PGBKQYRNRYVCCD-UHFFFAOYSA-N 0.000 claims 1
- NZCZNMGSFLEVRM-UHFFFAOYSA-N n-[[4-(2-chlorophenyl)piperazin-1-yl]methyl]benzamide Chemical compound ClC1=CC=CC=C1N1CCN(CNC(=O)C=2C=CC=CC=2)CC1 NZCZNMGSFLEVRM-UHFFFAOYSA-N 0.000 claims 1
- WHJYPPJWBWHYOC-UHFFFAOYSA-N n-[[4-(2-cyanophenyl)piperazin-1-yl]methyl]-2-methylbenzamide Chemical compound CC1=CC=CC=C1C(=O)NCN1CCN(C=2C(=CC=CC=2)C#N)CC1 WHJYPPJWBWHYOC-UHFFFAOYSA-N 0.000 claims 1
- FJYYLTSACBJXID-UHFFFAOYSA-N n-[[4-(2-cyanophenyl)piperazin-1-yl]methyl]-4-methylbenzamide Chemical compound C1=CC(C)=CC=C1C(=O)NCN1CCN(C=2C(=CC=CC=2)C#N)CC1 FJYYLTSACBJXID-UHFFFAOYSA-N 0.000 claims 1
- YVWOLSSJSAUBFF-UHFFFAOYSA-N n-[[4-(2-cyanophenyl)piperazin-1-yl]methyl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NCN(CC1)CCN1C1=CC=CC=C1C#N YVWOLSSJSAUBFF-UHFFFAOYSA-N 0.000 claims 1
- LAFUMJMKVVCEGP-UHFFFAOYSA-N n-[[4-(2-methoxyphenyl)piperidin-1-yl]methyl]-3-methylbenzamide Chemical compound COC1=CC=CC=C1C1CCN(CNC(=O)C=2C=C(C)C=CC=2)CC1 LAFUMJMKVVCEGP-UHFFFAOYSA-N 0.000 claims 1
- RLMPGZLIIPICGP-UHFFFAOYSA-N n-[[4-(3-cyanophenyl)piperazin-1-yl]methyl]-2-methylbenzamide Chemical compound CC1=CC=CC=C1C(=O)NCN1CCN(C=2C=C(C=CC=2)C#N)CC1 RLMPGZLIIPICGP-UHFFFAOYSA-N 0.000 claims 1
- HIEQCQJPNJXJSL-UHFFFAOYSA-N n-[[4-(3-cyanophenyl)piperazin-1-yl]methyl]-3-methylbenzamide Chemical compound CC1=CC=CC(C(=O)NCN2CCN(CC2)C=2C=C(C=CC=2)C#N)=C1 HIEQCQJPNJXJSL-UHFFFAOYSA-N 0.000 claims 1
- WYTHRCDFNJEOEP-UHFFFAOYSA-N n-[[4-(3-cyanopyridin-2-yl)piperazin-1-yl]methyl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NCN(CC1)CCN1C1=NC=CC=C1C#N WYTHRCDFNJEOEP-UHFFFAOYSA-N 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 2
- 102000005962 receptors Human genes 0.000 description 22
- 108020003175 receptors Proteins 0.000 description 22
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 21
- 229960003638 dopamine Drugs 0.000 description 12
- 125000000168 pyrrolyl group Chemical group 0.000 description 9
- 210000003016 hypothalamus Anatomy 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 5
- 102000030621 adenylate cyclase Human genes 0.000 description 4
- 108060000200 adenylate cyclase Proteins 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 230000018052 penile erection Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000000436 pro-erectile effect Effects 0.000 description 3
- 230000009329 sexual behaviour Effects 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- HTSNFXAICLXZMA-UHFFFAOYSA-N 3-(1-propyl-3-piperidinyl)phenol Chemical compound C1N(CCC)CCCC1C1=CC=CC(O)=C1 HTSNFXAICLXZMA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
- 229960004046 apomorphine Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 210000001009 nucleus accumben Anatomy 0.000 description 2
- 210000001010 olfactory tubercle Anatomy 0.000 description 2
- 210000002963 paraventricular hypothalamic nucleus Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000002509 periaqueductal gray Anatomy 0.000 description 2
- 210000003814 preoptic area Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NDCQPJCNZBQYAO-UHFFFAOYSA-N 4-[[3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC(C=2C3=CC=CC(=C3N=CC=2C(=O)C=2C=CC=CC=2)C(F)(F)F)=C1 NDCQPJCNZBQYAO-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001353 entorhinal cortex Anatomy 0.000 description 1
- 230000001257 erectogenic effect Effects 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000001748 islands of calleja Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- FTSUPYGMFAPCFZ-ZWNOBZJWSA-N quinpirole Chemical compound C([C@H]1CCCN([C@@H]1C1)CCC)C2=C1C=NN2 FTSUPYGMFAPCFZ-ZWNOBZJWSA-N 0.000 description 1
- 229950001037 quinpirole Drugs 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002813 septal nuclei Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000000542 thalamic effect Effects 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001030 ventral striatum Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Definitions
- the present invention relates to the use of acetamides and benzamides and compositions containing these compounds for the treatment of sexual dysfunction.
- DA dopamine
- PAG periaqueductal gray
- PAG periaqueductal gray
- PAG periaqueductal gray
- PNN paraventricular nucleus
- DA receptor agonists like apomorphine ((6aR) 5,6,6a,7- tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,l l-diol), quinpirole and (-) 3-(3- hydroxyphenyl)-N-propylpiperidine (3-PPP) facilitate penile erection in rats, an effect blocked by haloperidol, a central DA antagonist.
- DA receptor agonists like apomorphine ((6aR) 5,6,6a,7- tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,l l-diol), quinpirole and (-) 3-(3- hydroxyphenyl)-N-propylpiperidine (3-PPP) facilitate penile erection in rats, an effect blocked by haloperidol, a central DA antagonist.
- domperidone a peripheral DA antagonist
- Clinical data also indicates that DA systems in the CNS play a role on the regulation of male sexual behavior as indicated by the sexual stimulatory effect of L-dopa in Parkinson's patients and by the pro-erectile effect of apomorphine in humans.
- DA receptors belong to a superfamily of protein receptors that signal across the cell membrane by coupling to intracellular GTP-binding proteins.
- G proteins include Gs, Gq and Gi
- the Di-like receptors include Di and D 5 .
- the D 2 -like receptors include D 2 , D 3 and D 4 .
- the Di-like family receptor subtypes are G s -coupled and can activate adenylate cyclase.
- the D 2 -like family receptor subtypes are Gj-coupled and they increase intracellular calcium level and inhibit adenylate cyclase.
- the Di-like family members are G s -coupled receptors that can activate adenylate cyclase.
- the Di receptor is the most abundant and widespread DA receptor in the CNS both by mRNA expression and by immunohistochemical studies. It is found in the striatum, nucleus accumbens and olfactory tubercle as well as the limbic system, hypothalamus and thalamus.
- the Di receptor expression has been reported in the heart and kidney, and despite that the function of these peripheral Di receptors remains to be clarified, its role on the control of hemodynamic variables has been confirmed.
- the D 5 receptor while having a higher affinity for DA than the Di receptor, is sparsely distributed in the CNS with no evidence of expression outside the CNS. .
- the D 2 -like family members are Gi coupled receptors that inhibit adenylate cyclase and increase intracellular calcium levels.
- the D 2 receptor is the most abundant of the D 2 -like receptors and is located in brain areas such as the striatum and substantia nigra, and in peripheral areas such as the heart, pituitary gland and kidney.
- the D 3 receptor is found abundantly in the islands of Calleja with distinct cluster populations in the ventral striatum/nucleus accumbens regions, olfactory tubercle, dendate gyrus and striatal cortex.
- D 4 receptor has been documented by in situ RNA hybridization and immunohistochemical studies. Recently, studies revealed that D 4 expression is highest in the entorhinal cortex, lateral septal nucleus, hippocampus and the medial preoptic area of the hypothalamus. Localization of D 4 is distinct from the distribution of D 2 in the brain, as D 2 receptors are most abundant in striatal areas.
- the expression of D receptors in the MPOA of the hypothalamus is of importance to the facilitation of penile erection in view of the role of the hypothalamus as an area of integration between the cortex and the spinal pathways. The participation of D 4 receptors in other CNS regions, thalamic, subthalamic and spinal can not be excluded.
- the present invention identifies a therapeutic use for acetamides and benzamides of formula (I) in the treatment of sexual dysfunction in mammals. More specifically, these compounds are useful in the treatment of sexual dysfunction including, but not limited to, male erectile dysfunction (MED).
- MED male erectile dysfunction
- the present invention relates to a method of treating sexual dysfunction in a mammal, in particular humans, comprising administering to the mammal a therapeutically effective amount of a compound of formula (I)
- A is aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, or heterocyclealkyl;
- L is -N(R 7 )C(O)-, -C(O)N(R 7 )-, -N(R 7 )C(S)-, or-C(S)N(R 7 )- wherein the left end of said -N(R 7 )C(O)-, -C(O)N(R 7 )-, -N(R 7 )C(S)-, or -C(S)N(R 7 )- is attached to A and the right end is attached to D;
- D is alkylene, fluoroalkylene, or hydroxyalkylene
- Z is N, C or CR B ;
- R A is hydrogen or alkyl
- R B is hydrogen, alkyl, or halogen
- — is a bond when Z is C and — is absent when Z is N or CR B ;
- Ri, R 2 , R 3 , R 4 and R5 are each independently hydrogen, alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, -NZ ⁇ Z 2 , (NZ 3 Z 4 )alkyl, (NZ 3 Z 4 )carbonyl, or (NZ 3 Z 4 )sulfonyl;
- Zi and Z 2 are each independently hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, arylalkyl, arylalkylsulfonyl, arylsulfonyl, or formyl;
- Z 3 and Z 4 are each independently hydrogen, alkyl, aryl, or arylalkyl
- Y is C(R ) or N
- R 6 is hydrogen or alkyl
- R 7 is hydrogen or alkyl.
- the present invention relates to a method of treating sexual dysfunction in a mammal, in particular humans, comprising administering to the mammal a therapeutically effective amount of a compound of formula (I)
- A is aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, or heterocyclealkyl;
- L is -N(R 7 )C(O)-, -C(O)N(R 7 )-, -N(R 7 )C(S)-, or-C(S)N(R 7 )- wherein the left end of said -N(R 7 )C(O)-, -C(O)N(R 7 )-, -N(R 7 )C(S)-, or -C(S)N(R 7 )- is attached to A and the right end is attached to D;
- D is alkylene, fluoroalkylene, or hydroxyalkylene
- Z is N, C or CR B ;
- RA is hydrogen or alkyl
- RB is hydrogen, alkyl, or halogen
- — is a bond when Z is C and — is absent when Z is N or CR B ;
- Ri, R 2 , R 3 , R 4 and R 5 are each independently hydrogen, alkoxy, alkenyl, alkyl, alkylsulfmyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, -NZ ⁇ Z 2 , (NZ 3 Z 4 )alkyl, (NZ 3 Z 4 )carbonyl, or (NZ 3 Z )sulfonyl;
- Zi and Z 2 are each independently hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, arylalkyl, arylalkylsulfonyl, arylsulfonyl, or formyl;
- Z 3 and Z are each independently hydrogen, alkyl, aryl, or arylalkyl
- X is N(R 6 ), O or S
- Y is C(R 4 ) or N
- R 6 is hydrogen or alkyl
- R 7 is hydrogen or alkyl.
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
- R l3 R 2 , R 3 , R 4 , R 5 , R 7 , and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy;
- R 3 is hydrogen or hydroxy;
- R 4 and R 5 are hydrogen;
- Z is N; — is absent;
- D is -CH 2 -;
- L is -N(R 7 )C(O)-; and
- R and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Rj is hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, hydroxy, nitro, -
- NZ ⁇ Z 2 , or (NZ 3 Z )alkyl R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy; R 3 is hydrogen or hydroxy; R 4 and R 5 are hydrogen; Z is N; — is absent; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; and R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
- B is
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen,
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or
- NZ 3 Z 4 carbonyl
- R 2 and R 4 are hydrogen; R 3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and RA are as defined on formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z 4 )carbonyl;
- R 2 and R 4 are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is N; — is absent;
- D is -CH 2 -;
- L is -N(R 7 )C(S)-; and
- R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl; R 2 and are hydrogen; R 3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH(CH 3 )-; L is -N(R 7 )
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is tetrahydronaphthalenyl or 2,3-dihydro-lH-indenyl; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- NZ 3 Z 4 carbonyl
- R 2 and Rt are hydrogen; R3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH 2 -; L is -N(R )C(O)-; and R 7 and RA are as defined in formual (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is tetrahydronaphthalenyl or 2,3-dihydro-lH-indenyl; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
- R 2 and R 4 are hydrogen;
- R3 is hydrogen or hydroxy;
- Z is N; — is absent;
- D is -CH(CH 3 )-;
- L is -N(R 7 )C(O)-; and
- R and R A are as defined in formual (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is z is N . ... is absent .
- L is _N(R 7 )C(O)-; and D, R, , R 2 , R 3 ,
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
- B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- NZ 3 Z carbonyl
- R 2 and R 4 are hydrogen; R 3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and R A are as defined on formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl wherein the heterocycle is independently substituted with 0, 1 , 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
- Ri is hydrogen, alkyl, cyaiio, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- NZ 3 Z carbonyl
- R 2 and R 4 are hydrogen; R 3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH 2 -; L is -N(R )C(O)-; and R 7 and R A are as defined on formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is Z is N; — is absent; L is -N(R 7 )C(O)-; and D, R 2 , R 3 , i, R 7 , and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- R 2 , R 3 , and R 4 are hydrogen; Z is N; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)- ; and R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is R 2 N ' ⁇ / R 3
- a 4 - ⁇ j ⁇ an( j j ⁇ are hydrogen; Z is N; — is absent; D is -CH(CH 3 )-; L is - N(R )C(O)-; and R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
- L is -N(R 7 )C(O)-; and D, X, Y, R 2 , R 3 , R 7 , and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ[Z 2 ; B is
- R 2 and R 3 are hydrogen; X is N(R 6 ), O, or S; Y is N; Z is N; — is absent; D is
- R_, R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- R 2 and R 3 are hydrogen; X is N(R 6 ), O, or S; Y is N; Z is N; — is absent; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; and R 6 , R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle; B is
- R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
- B is
- N . ... is absent .
- D is . CH .
- L is -N(R 7 )C(O)-; and R, , R 2 , R 3 , R t , R 7 and RA are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
- B is
- D is _ C H(CH 3 )-; L is -N(R 7 )C(O)-; and R,, R 2 , R 3 , R A , R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
- Ri is the group consisting of hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
- R 2 and RA are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is N; — is absent;
- D is -CH 2 -;
- L is -N(R 7 )C(O)-; and
- R 7 and R A are as defined in formula
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
- Ri is the group consisting of hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl; R 2 and R 4 are hydrogen; R is hydrogen or hydroxy;
- Z is N; — is absent; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; and R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl; B is
- R u R 2 , R 3 , R A , R I , and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- NZ 3 Z carbonyl
- R 2 and R are hydrogen; R 3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH -; L is -N(R 7 )C(O)-; and R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is .
- NZ 3 Z 4 carbonyl
- R 2 and R 4 are hydrogen; R 3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; and R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is arylalkyl; B is
- z is N; — is absent; L is -N(R 7 )C(O)-; and D, Ri, R 2 , R 3 , R A , R 7 , and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is arylalkyl wherein the aryl of arylalkyl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- NZ 3 Z 4 carbonyl
- R 2 and R 4 are hydrogen; R3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and RA are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is arylalkyl wherein the aryl of arylalkyl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ[Z 2 ; B is is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or
- NZ3Z 4 carbonyl; R and R are hydrogen; R3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; and R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
- Z is CR B ; — is absent; L is -N(R 7 )C(O)-; and D, Ri, R 2 , R 3 , R 4 , R 5 , R 7 , R B , and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, and -NZ[Z 2 ; B is
- Ri is hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, hydroxy, nitro, -
- NZ ⁇ Z 2 , or (NZ 3 Z )alkyl R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy; R 3 is hydrogen or hydroxy; Rj and R 5 are hydrogen; Z is CR B ; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; R B is hydrogen; and R 7 and RA are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ_Z 2 ; B is is hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, hydroxy, nitro, -
- NZ ⁇ Z 2 , or (NZ 3 Z 4 )alkyl R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy; R 3 is hydrogen or hydroxy; R 4 and R 5 are hydrogen; Z is CR B ⁇ — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; R B is halogen wherein a preferred halogen is -F; and R 7 and RA are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- R l is hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, hydroxy, nitro, -
- R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy;
- R 3 is hydrogen or hydroxy;
- 4 and R 5 are hydrogen;
- Z is CR B ; — is absent;
- D is -CH(CH 3 )-;
- L is -N(R 7 )C(O)-;
- R B is hydrogen; and
- R 7 and RA are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
- Z is CR B ; — is absent; L is -N(R 7 )C(O)-; R B is hydrogen; and D, R u R 2 , R 3 ,
- R 4 , R 7) and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl; R 2 and RA are hydrogen; R 3 is hydrogen or hydroxy; Z is CRB; — is absent; D is -CH 2 -; L is -N(R 7 )
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is tetrahydronaphthalenyl or 2,3-dihydro-lH-indenyl; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z 4 )carbonyl;
- R 2 and R are hydrogen;
- R3 is hydrogen or hydroxy;
- Z is CR B ;
- — is absent;
- D is -CH 2 -;
- L is -N(R 7 )C(S)-;
- R B is hydrogen; and R 7 and R A are as defined on formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; R B is hydrogen; and R , R B , and R A are as defined on formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
- B is
- RA, R ⁇ , and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
- B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
- R] is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z 4 )carbonyl;
- R 2 and R 4 are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is CRB; — is absent;
- D is -CH 2 -;
- L is -N(R 7 )C(O)-;
- RB is hydrogen; and
- R 7 and R A are as defined on formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ 1 Z 2 ; B is
- X is N(Rs), O, or S; Y is N; R 2 and R 3 are hydrogen; Z is CR B ; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; R B is hydrogen; and R_, R 7 and RA are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZjZ 2 ; B is ; X is N(R 6 ), O, or S; Y is N; R 2 and R 3 are hydrogen; Z is CR B ; — is absent; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; R B is hydrogen; and Re, R 7 and R A are as defined in formula (I) wherein A is aryl wherein
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- z is CR B ; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; R 2 , R 3 , and j are hydrogen; R B is hydrogen; and R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
- R is CR B ; — is absent; L is -N(R 7 )C(O)-; and D, R,, R 2 , R 3 , 4 , R 7 , R B , and RA are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri, R 2 , R 3 , and R are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is
- R 7 and RA are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- R ls R 2 , R 3) and RA are hydrogen; Z is CR B ; RB is hydrogen; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and R A are hydrogen.
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 1 alkyl substituent; B is
- R 1 ⁇ R 2 , R 3 , and RA are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and R A are hydrogen.
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 1 alkyl substituent; B is
- R ⁇ , R 2 , R 3 , and RA are hydrogen; Z is CRB; R B is hydrogen; — is absent; D is
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri, R 2 , R 3 , and R are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; and R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is tetrahydronaphthalenyl or 2,3-dihydro-lH-indenyl; B is Ri, R 2 , R3, and j are hydrogen; Z is CRB; RB is hydrogen; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and R A are hydrogen.
- A is aryl wherein the aryl is tetrahydronaphthalenyl or 2,3-dihydro-lH-indenyl
- B Ri, R 2 , R3, and j are hydrogen
- Z is CRB
- RB is hydrogen
- — is absent
- D is -CH 2 -
- L is -N(R 7 )C(O)-
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
- B is
- Z is CR B ;
- R B is hydrogen; — is absent;
- L is -N(R 7 )C(O)-; and
- D, R u R 2 , R 3 , R A , R 7 , and RA are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
- B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
- R 2 and R are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is CR B ;
- RB is hydrogen;
- — is absent;
- D is -CH 2 -;
- L is -N(R 7 )C(O)-; and
- R 7 and RA are as defined on formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z )carbonyl;
- R 2 and R A are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is CR B ;
- R B is hydrogen;
- — is absent;
- D is -CH 2 -;
- L is -N(R )C(O)-; and
- R 7 and R A are as defined on formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl; B is
- R u R 2 , R 3 , R 4 , R 7 , R B , and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z )carbonyl;
- R 2 and R are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is CR B ;
- R B is hydrogen;
- — is absent;
- D is -CH 2 -;
- L is -N(R 7 )C(O)-; and
- R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- NZ 3 Z carbonyl
- R 2 and RA are hydrogen; R 3 is hydrogen or hydroxy; Z is CRB; RB is hydrogen; — is absent; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; and R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
- R R 2 , R 3 , RA, R 5 , R 7 , and R A are as defined on formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZjZ 2 ; B is
- R ! is hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, hydroxy, nitro, -
- R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy;
- R 3 is hydrogen or hydroxy;
- RA and R 5 are hydrogen;
- Z is C; — is a bond;
- D is -CH 2 -;
- L is -N(R 7 )C(O)-; and
- R 7 and RA are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is ; R ! is hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, hydroxy, nitro, -
- NZ ⁇ Z 2 , or (NZ 3 Z )alkyl R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy; R 3 is hydrogen or hydroxy; RA and R 5 are hydrogen; Z is C; — is a bond; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; and R 7 and RA are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
- R z is C; — is a bond; L is -N(R 7 )C(O)-; and D, R x , R 2 ,R 3 , R 4 , R 7 , and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is R ⁇ i s hydroge , alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z )carbonyl; R 2 and R 4 are hydrogen; R 3 is hydrogen or hydroxy; Z is C; — is a bond; D is -CH(CH 3 )-;
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
- B is
- Z is C; — is a bond; L is -N(R 7 )C(O)-; and D, R b R 2 , R 3 , Rt, R 7 , and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
- B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z )carbonyl;
- R 2 and R 4 are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is C; — is a bond;
- D is -CH 2 -;
- L is -N(R 7 )C(O)-; and
- R 7 and R A are as defined on formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
- z ig c . __. is a bond . L . is . N ( R7 ) (o). ; and D, X, Y, R 2 , R 3 , R 7 , and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
- X is N(R 6 ), O, or S; Y is C(R 4 ); R 2 and R 3 are hydrogen; R 4 is hydrogen, alkyl, or cyano; Z is C; — is a bond; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 6 , R , and RA are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is ; X is N(R 6 ), O, or S; Y is C(R- t ); R 2 and R 3 are hydrogen; RA is hydrogen, alkyl, or cyano; Z is C; — is a bond; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; and R 6 , R 7 and
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl; B is
- R u R 2 , R 3 , R 4 , R 7 , and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- NZ 3 Z carbonyl
- R 2 and R are hydrogen; R3 is hydrogen or hydroxy; Z is C; — is a bond; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and RA are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
- R s hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
- R l s R 2 , R 3 , RA, R 5 , R 7 , and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- R ⁇ is hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, hydroxy, nitro, -
- R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy;
- R 3 is hydrogen or hydroxy;
- R and R 5 are hydrogen;
- Z is N; — is absent;
- D is -CH 2 -;
- L is -C(0)N(R 7 )-; and
- R 7 and RA are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri is hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, hydroxy, nitro, -
- R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy;
- R 3 is hydrogen or hydroxy;
- R 4 and R 5 are hydrogen;
- Z is N; — is absent;
- D is -CH(CH 3 )-;
- L is -C(O)N(R 7 ; and
- R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z )carbonyl;
- R 2 and R are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is N; — is absent;
- D is -CH 2 -;
- L is -C(O)N(R 7 )-; and
- R and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z )carbonyl;
- R 2 and R 4 are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is N; — is absent;
- D is -CH(CH 3 )-;
- L is -C(O)N(R 7 )-; and
- R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ[Z 2 ; B is
- R! is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- NZ 3 Z 4 carbonyl
- R and R4 are hydrogen; R 3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH 2 CH 2 -; L is -C(O)N(R )-; and R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
- L is -C(0)N(R 7 ; and D, R 2 , R 3 , R A , R 7 , and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- R 2 , R 3 , and 4 are hydrogen; Z is N; — is absent; D is -CH(CH 3 )-; L is -C(O)N(R 7 )-; and R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl; B is
- Z is N; — is absent; L is -C(O)N(R 7 )-; and D, Ri, R 2 , R 3 , R , R 7 , and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- R 2 and R_ % are hydrogen; R 3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R and R A are as defined as in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
- Z is CR B ;
- RB is hydrogen;
- — v is absent;
- L is -C(O)N(R 7 )-; and D, R R 2 , R 3 ,
- RA, R 5 , R7, and RA are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
- Ri is hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, hydroxy, nitro, -
- NZ]Z 2 or (NZ 3 Z )alkyl
- R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy
- R 3 is hydrogen or hydroxy
- R 4 and R 5 are hydrogen
- Z is CR B
- R B is hydrogen
- — is absent
- D is -CH 2 -
- L is -C(O)N(R 7 )-
- R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri is hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, hydroxy, nitro, -
- R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy;
- R 3 is hydrogen or hydroxy;
- j and R 5 are hydrogen;
- Z is CR B ;
- R B is hydrogen; — is absent;
- D is -CH(CH 3 )-;
- L is -C(O)N(R 7 )-; and
- R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
- R ⁇ is hydrogen; — is absent; L is -C(O)N(R 7 )-; and D, R 1; R 2 , R 3 , R 4 , R 7 , and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z 4 )carbonyl;
- R 2 and RA are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is CR B ;
- R B is hydrogen; — is absent;
- D is -CH(CH )-;
- L is -C(O)N(R 7 )-; and
- R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkeriyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Z is CR B ;
- R B is hydrogen; — is absent; D is - CH 2 -; L is -C(O)N(R 7 )-; and
- R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZjZ 2 ; B is
- R B is hydrogen; — is absent; D is CH(CH 3 )-; L is -C(O)N(R 7 )-; and R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is Z is CR B ; R B is hydrogen; — is absent; L is -C(O)N(R 7 )-; and D, R R 2 , R 3 , R , R 7 , and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri, R 2 , R 3 , and RA are hydrogen; Z is CRB; R B is hydrogen; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and R are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri, R 2 , R 3 , and R 4 are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and R A are hydrogen.
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 1 alkyl substituent; B is ; Ri, R 2 , R 3 , and R A are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and R A are hydrogen.
- A is aryl wherein the aryl is phenyl substituted with 1 alkyl substituent
- B is ;
- Ri, R 2 , R 3 , and R A are hydrogen;
- Z is CR B ;
- R B is hydrogen; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and R A are hydrogen.
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 1 alkyl substituent wherein a preferred alkyl substituent is methyl; B is
- Ri, R 2 , R 3 , and R 4 are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and R A are hydrogen.
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 1 alkyl substituent wherein a prefened alkyl substituent is methyl; B is
- Ri, R 2 , R 3 , and R are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -C(S)N(R 7 )-; and R 7 and R A are hydrogen.
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri, R 2 , R 3 , and RA are hydrogen; Z is CRB; RB is hydrogen; — is absent; D is -CH(CH 3 )-; L is -C(O)N(R 7 )-; and R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 1 alkyl substituent wherein a prefened alkyl substituent is methyl; B is
- Ri, R 2 , R 3 , and R A are hydrogen; Z is CRB; R B is hydrogen; — is absent; D is -CH(CH 3 )-; L is -C(O)N(R 7 )-; and R 7 and R A are hydrogen.
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
- B is
- Z is CR B ;
- R B is hydrogen; — is absent;
- L is -C(O)N(R 7 )-; and
- D, Ri, R 2 , R 3 , R t , R 7 , and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is , benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is ; Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl,
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl wherein the heterocycle is independently substituted with 0, 1 , 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- R 2 and RA are hydrogen; R 3 is hydrogen or hydroxy; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and R A are as defined on formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl; B is
- Z is CR B ;
- R B is hydrogen; — is absent;
- L is -C(O)N(R 7 )-; and D, R ls R 2 , R 3 ,
- RA, R 7 , and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is ; Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- R 2 and I are hydrogen; R 3 is hydrogen or hydroxy; Z is CRB; RB is hydrogen; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and RA are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl,
- R 2 and RA are hydrogen; R 3 is hydrogen or hydroxy; Z is CR B ; R B is hydrogen; — is absent; D is -CH(CH 3 )-; L is -C(O)N(R 7 )-; and R 7 and RA are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
- R R 2 , R 3 , RA, R 5 , R 7 , and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is ; Ri is hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, hydroxy, nitro, - NZ ⁇ Z 2 , or (NZ 3 Z )alkyl; R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy; R 3 is hydrogen or hydroxy; R 4 and R 5 are hydrogen; Z is C;
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy;
- R 3 is hydrogen or hydroxy;
- R A and R 5 are hydrogen;
- Z is C; — is a bond;
- D is -CH(CH 3 )-;
- L is -C(O)N(R 7 )-; and
- R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
- R R 2 , R 3 , R 4 , R 7 , and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- R 2 and RA are hydrogen; R 3 is hydrogen or hydroxy; Z is C; — is a bond; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and RA are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- R 2 and RA are hydrogen; R 3 is hydrogen or hydroxy; Z is C; — is a bond; D is -CH(CH 3 )-; L is -C(O)N(R 7 )-; and R 7 and RA are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is naphthyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- R 2 and R are hydrogen; R 3 is hydrogen or hydroxy; Z is C; — is a bond; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and RA are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is naphthyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- R 2 and RA are hydrogen; R 3 is hydrogen or hydroxy; Z is C; — is a bond; D is -CH(CH 3 )-; L is -C(O)N(R 7 )-; and R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- R 2 and R 3 are hydrogen; X is N(R 6 ), O, or S; Y is N; Z is C; — is a bond; D is -CH 2 -; L is -C(O)N(R 7 )-; and R$, R 7 , and RA are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is R 2 and R 3 are hydrogen; X is N(R 6 ), O, or S; Y is N; Z is C; — is a bond; D is
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl; B is
- Z is C; — is a bond; L is -C(O)N(R 7 )-; and D, R b R 2 , R 3 , R A , R 7 , and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
- Rl ig hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
- R 2 and RA are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is C; — is a bond;
- D is -CH 2 -;
- L is -C(O)N(R 7 )-; and
- R 7 and R A are as defined in formula (I).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is R 2
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
- R 2 and RA are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is C; — is a bond;
- D is -CH(CH 3 )-;
- L is -C(O)N(R 7 )-; and
- R 7 and R A are as defined in formula (I).
- the present invention relates to compounds of formula (II)
- A is aryl, arylalkyl, cycloalkyl, or cycloalkylalkyl;
- L is -N(R 7 )C(O)-, -C(O)N(R 7 )-, -N(R 7 )C(S)-, or -C(S)N(R 7 )- wherein the left end of the -N(R 7 )C(O)-, -C(O)N(R 7 )-, -N(R 7 )C(S)-, and -C(S)N(R 7 )- is attached to A and the right end is attached to D;
- D is alkylene, fluoroalkylene, or hydroxyalkylene
- Z is selected from N, C or CR B ;
- R A is hydrogen or alkyl
- R B is hydrogen, alkyl, or halogen
- — is a bond when Z is C and — is absent when Z is N or CRB;
- Ri, R 2 , R 3 , and R ⁇ are each independently hydrogen, alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, -NZ ⁇ Z 2 , (NZ 3 Z 4 )alkyl, (NZ 3 Z 4 )carbonyl, or (NZ 3 Z 4 )suIfonyl;
- Zi and Z 2 are each independently hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, arylalkyl, arylalkylsulfonyl, arylsulfonyl, or formyl;
- Z 3 and Z 4 are each independently hydrogen, alkyl, aryl, or arylalkyl
- X is N(R 6 ), O, or S
- Y is C(R 4 ) orN
- R 6 is hydrogen or alkyl
- R 7 is hydrogen or alkyl.
- compounds of formula (II) are disclosed wherein A is aryl; B is
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z ; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
- R 2 and R 4 are hydrogen;
- R3 is hydrogen or hydroxy;
- Z is N; — is absent;
- D is -CH 2 -;
- L is -N(R 7 )C(O)-; and
- R 7 arid RA are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ[Z 2 ; B is
- R . i hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- compounds of formula (II) wherein A is aryl wherein the aryl is tetrahydronaphthalenyl or 2,3-dihydro-lH- indenyl; B is from hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl; R 2 and R A are hydrogen; R 3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and RA are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- NZ 3 Z carbonyl
- R 2 and ; are hydrogen; R 3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH 2 -; L is -N(R 7 )C(S)-; and R 7 and R A are as defined in formula (II).
- compounds of formula (II) wherein A is aryl wherein the aryl is tetrahydronaphthalenyl or 2,3-dihydro-lH- indenyl; B is
- N; — is absent; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; and R 7 and RA are as defined in formula
- compounds of formula (II) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is Z is N; — is absent; L is -N(R 7 )C(O)-; and D, Rj , R 2 , R 3 , R 4 , R 7 , and R A are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
- B is
- R t is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, (NZ 3 Z 4 )carbonyl;
- R 2 and R 4 are hydrogen;
- R3 is hydrogen or hydroxy;
- Z is N; — is absent;
- D is -CH 2 -;
- L is -N(R 7 )C(O)-; and
- R 7 and R A are as defined on formula (II).
- compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- NZ 3 Z carbonyl
- R 2 and R 4 are hydrogen; R3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R and RA are as defined on formula (II).
- Z is N; — is absent; L is -N(R 7 )C(O)-; and D, R 2 , R 3 , R 4 , R 7 , and R A are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- R and R A are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents 1 independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- R 7 and R are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ[Z 2 ; B is
- R 2 and R 3 are hydrogen; X is N(R 6 ), O, or S; Y is N; Z is N; — is absent; D is
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
- R 2 and R 3 are hydrogen; X is N(Re), O, or S; Y is N; Z is N; — is absent; D is
- R 6 , R 7 , and R A are as defined in formula (II).
- compounds of formula (II) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z )carbonyl;
- R 2 and R are hydrogen;
- R3 is hydrogen or hydroxy;
- Z is N; — is absent;
- D is -CH 2 -;
- L is -N(R 7 )C(O)-; and
- R 7 and R A are as defined in formula (II).
- compounds of formula (II) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- A is arylalkyl wherein the aryl of arylalkyl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZiZ 2 ; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
- R 2 and R are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is N; — is absent;
- D is -CH 2 -;
- L is -N(R 7 )C(O)-; and
- R 7 and R are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is arylalkyl wherein the aryl of arylalkyl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected frorh alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZiZ 2 ;
- B is -
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
- R 2 and R 4 are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is N; — is absent;
- D is -CH(CH 3 )-;
- L is -N(R 7 )C(O)-; and
- R 7 and R A are as defined in formula (II).
- R u R 2 , R 3 , R 4 , R 7 , R B , and R A are as defined in formula (II).
- compounds of formula (II) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ;
- B is Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
- R 2 and Rt are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is CR B ;
- RB is hydrogen; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and R A are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- (NZ 3 Z 4 )carbonyl, or (NZ 3 Z 4 )carbonyl; R 2 and t are hydrogen; R 3 is hydrogen or hydroxy; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -N(R )C(S)-; and R and RA are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
- R t is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is Z is CR B ; — is absent; L is -N(R 7 )C(O)-; R B is hydrogen; and D, Ri, R 2; R 3 ,
- RA, R 7 , and RA are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
- B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- Y Rs ; Z is CR B ; — is absent; L is -N(R 7 )C(O)-; and D, X, Y, R 2 , R 3 , R 7 , R B , and R A are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ 1 Z 2 ; B is
- X is N(R 6 ), O, or S; Y is N; R 2 and R 3 are hydrogen; Z is CR B ; R B is hydrogen;
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- X is N(R 6 ), O, or S; Y is N; R 2 and R 3 are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; and R 6 , R 7 and RA are as defined in formula (II).
- z is CR ⁇ . ... ig absent; L is -N(R 7 )C(O)-; and D, R 2 , R 3 , R+, R 7 , R B , and R A are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ 1 Z 2 ; B is
- z is CR B ;
- R B is hydrogen; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; R 2 , R 3 , and R are hydrogen; and R 7 and RA are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; R 2 , R 3 , and 4 are hydrogen; and R 7 and R A are as defined in formula (II).
- R b R 2 , R 3 , R 4 , R 7 , R B , and R A are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
- Ri, R 2 , R 3 , and RA are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and R A are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri, R 2 , R 3 , and R 4 are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and R A are hydrogen.
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri, R 2 , R 3 , and R 4 are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is
- R 7 and R A are as defined in formula (II).
- compounds of formula (II) wherein A is aryl wherein the aryl is tetrahydronaphthalenyl or 2,3-dihydro-lH- indenyl; B is
- Ri, R 2 , R 3 , and R A are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is
- R 7 and R A are hydrogen.
- compounds of formula (II) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
- B is Z is CR B ;
- R B is hydrogen; — is absent;
- L is -N(R 7 )C(O)-;
- D, R h R 2 , R 3 , R t , R 7 , and R A are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
- B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z )carbonyl;
- R 2 and Rt are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is CR B ;
- R B is hydrogen;
- — is absent;
- D is -CH 2 -;
- L is -N(R 7 )C(O)-; and
- R 7 and R A are as defined on formula (II).
- compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z )carbonyl;
- R 2 and R A are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is CR B ;
- RB is hydrogen; — is absent;
- D is -CH 2 -;
- L is -N(R 7 )C(O)-; and
- R 7 and RA are as defined on formula (II).
- compounds of formula (II) wherein A is cycloalkyl; B is Z is CR B ; — is absent; L is -N(R 7 )C(O)-; and D, R] , R 2 , R 3 , R 4 , R 7 , R B , and R A are as defined in formula (II).
- compounds of formula (II) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or _>
- NZ 3 Z carbonyl
- R 2 and RA are hydrogen; R 3 is hydrogen or hydroxy; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and R A are as defined in formula (II).
- compounds of formula (II) are . disclosed wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
- R 2 and * are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is CR B ;
- RB is hydrogen;
- — is absent;
- D is -CH(CH 3 )-;
- L is -N(R 7 )C(O)-; and
- R and RA are as defined in formula (II).
- compounds of formula (II) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ;
- B is Rj is hydrogen, alkyl, cyano, halolalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ3Z 4 )carbonyl;
- R 2 and R 4 are hydrogen;
- R is hydrogen or hydroxy;
- Z is C; — is a bond;
- D is -CH 2 -;
- L is -N(R 7 )C(O)-; and
- R 7 and R A are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
- B is
- z is C; — is a bond; L is -N(R 7 )C(O)-; R B is hydrogen; and D, R h R 2 , R 3 , A , R ⁇ , and R A are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
- B is Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- R 2 and R A are hydrogen; R 3 is hydrogen or hydroxy; Z is C; — is a bond; D is -CH 2 -; L is -N(R 7 )C(O)-; RB is hydrogen; and R 7 and R A are as defined on formula (II).
- compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
- X is N(R 6 ), O, or S
- Y is C(R 4 );
- R 2 and R 3 are hydrogen;
- R 4 is hydrogen, alkyl, or cyano;
- Re, R 7 , and R are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- X is N(R 6 ), O, or S; Y is C(R 4 ); R 2 and R 3 are hydrogen; t is hydrogen, alkyl, or cyano; Z is C; — is a bond; D is -CH(CH 3 )-; L is -N(R )C(O)-; and R 6 , R 7 , and R A are as defined in formula (II).
- R 7 , and R A are as defined in formula (II).
- compounds of formula (II) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
- compounds of formula (II) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ Z 4 )carbonyl;
- R 2 and R 4 are hydrogen;
- R3 is hydrogen or hydroxy;
- Z is C; — is a bond;
- D is -CH(CH 3 )-;
- L is -N(R 7 )C(O)-; and
- R 7 and R A are as defined in formula (II).
- compounds of formula (II) wherein A is aryl; B is ; Z is N; — is absent; L is -C(O)N(R 7 )-; and D, R h R 2 , R 3 , R 4 , R 7 , and R A are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- R 2 and RA are hydrogen; R 3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and RA are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ 1 Z 2 ; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- R 2 , R 3 , and R A are hydrogen; Z is N; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )- ; and R 7 and R A are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- R 2 , R 3 , and A are hydrogen; Z is N; — is absent; D is -CH(CH 3 )-; L is - C(O)N(R )-; and R 7 and R A are as defined in formula (II).
- z is N . ... i s absen t; L is -C(O)N(R 7 )-; and D, Ri , R 2 , R 3 , R A , R 7 , and R A are as defined in formula (II).
- A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl;
- B is Rj j ., hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z )carbonyl;
- R 2 and * are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is N; — is absent;
- D is -CH 2 -;
- L is -C(O)N(R 7 )-; and
- R 7 and R A are as defined in formula (II).
- compounds of formula (II) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nifro, (NZ 3 Z )alkyl, or (NZ 3 Z 4 )carbonyl;
- R 2 and 4 are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is N; — is absent;
- D is -CH(CH 3 )-;
- L is -C(O)N(R 7 )-; and
- R 7 and R A are as defined in formula (II).
- Z is CR B ; — is absent; L is -C(O)N(R 7 )-; and D, R ⁇ , R z , R 3 , R A , R ⁇ , R B , and R A are as defined in formula (Et).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- R 2 and R A are hydrogen; R 3 is hydrogen or hydroxy; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and R A are as defined in formula (II).
- compounds of formula (II) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is ; Rj is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z 4 )carbonyl; R 2 and R A are hydrogen; R 3 is hydrogen or hydroxy; Z is CR B ; R B is hydrogen; — is absent; D is -CH(CH 3 )-; L is -C(O)N(R 7 )-; and R 7 and R A are as defined in formula (
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZjZ 2 ; B is
- R 7 and R A are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZjZ 2 ; B is
- R 7 and R A are as defined in formula (II).
- compounds of formula (II) wherein A is aryl; B is Z is CR B ; — is absent; L is -C(O)N(R 7 )-; and D, Ri, R 2 , R 3 , R A , R 7 , R B , and R A are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri, R 2 , R 3 , and R A are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -C(O)N(R )-; and R and R A are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
- R 7 and R A are hydrogen.
- compounds of formula (II) wherein A is aryl wherein the aryl is phenyl substituted with 1 alkyl substituent; B is
- R 2 , R 3 , and R 4 are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and R A are hydrogen.
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 1 alkyl substituent wherein a prefened alkyl substituent is methyl; B is
- R B is hydrogen; — is absent; D is -CH2-; L is -C(O)N(R 7 )-; and R 7 and R A are hydrogen.
- compounds of formula (II) wherein A is aryl wherein the aryl is phenyl substituted with 1 alkyl substituent wherein a prefened alkyl substituent is methyl; B is
- R 7 and R A are hydrogen.
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, allcythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- R b R 2 , R , and R 4 are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH(CH 3 )-; L is -C(O)N(R 7 )-; and R 7 and R A are as defined in formula (II).
- compounds of formula (II) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
- B is ;
- Z is CR B ;
- R B is hydrogen; — is absent;
- L is -C(O)N(R 7 )-; and D, Ri, R 2 , R 3 ,
- R4, R 7 , and R A are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
- B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z )carbonyl;
- R 2 and * are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is CR B ;
- R B is hydrogen;
- — is absent;
- D is -CH 2 -;
- L is -C(O)N(R 7 )-; and
- R 7 and R A are as defined on formula (II).
- compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
- Rj is hydrogen, alkyl, cyano, haloalkyl, halogen, nifro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
- R 2 and R 4 are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is CR B ;
- R B is hydrogen;
- — is absent;
- D is -CH 2 -;
- L is -C(O)N(R )-; and
- R 7 and R A are as defined on formula (II).
- compounds of formula (II) wherein A is cycloalkyl; B is Z is CR B ; — is absent; L is -C(O)N(R 7 )-; and D, R 1; R 2 , R 3 , R 4 , R 7 , R B , and
- R A are as defined in formula (II).
- compounds of formula (II) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
- R 2 and A are hydrogen; R 3 is hydrogen or hydroxy; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R and R A are as defined in formula (II).
- compounds of formula (II) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z 4 )carbonyl;
- R 2 and R are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is CR B ;
- R B is hydrogen;
- — is absent;
- D is -CH(CH 3 )-;
- L is -C(O)N(R 7 )-; and
- R and R A are as defined in formula (II).
- z is C; — is a bond; L is -C(O)N(R 7 )-; and D, Ri , R 2 , R 3 , R A , R 7 , and R A are as defined in formula (II).
- compounds of formula (II) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ;
- B is Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nifro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
- R 2 and R 4 are hydrogen;
- R 3 is hydrogen or hydroxy;
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1 , 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nifro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
- R and R A are hydrogen;
- R3 is hydrogen or hydroxy;
- Z is C;
- — is a bond;
- D is -CH(CH 3 )-;
- L is -C(O)N(R 7 )-; and
- R 7 and R A are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is naphthyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri is hydrogen, alkyl, cyano, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z 4 )carbonyl;
- R 2 , R 3 , and R A axe hydrogen;
- Z is C;
- — is a bond;
- D is -CH 2 -;
- L is -C(O)N(R 7 )-; and
- R and R A are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is naphthyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nifro, phenyl, or -NZ]Z 2 ; B is l 2
- Rj is hydrogen, alkyl, cyano, haloalkyl, halogen, nifro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
- R 2 and are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is C; — is a bond;
- D is -CH(CH 3 )-;
- L is -C(O)N(R 7 )-; and
- R 7 and R A are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl; B is
- Z is C; — is a bond; L is -C(O)N(R 7 )-; and D, X, Y, R 2 , R 3 , R 7 and R A are as defined in formula (II).
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- R 2 and R 3 are hydrogen; X is N(Rg), O, or S; Y is N; Z is C; — is a bond; D is
- compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- R 2 and R 3 are hydrogen; X is N(R 6 ), O, or S; Y is N; Z is C; — is a bond; D is
- L is _ C (0)N(R 7 )-; and D, R ls R 2 , R 3 , R A , R 7 , and R A are as defined in formula (II).
- compounds of formula (II) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is l 2
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- R 2 and A are hydrogen; R 3 is hydrogen or hydroxy; Z is C; — is a bond; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and R A are as defined in formula (II).
- compounds of formula (II) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z 4 )carbonyl;
- R 2 and R A are hydrogen;
- R 3 is hydrogen or hydroxy;
- Z is C;
- — is a bond;
- D is -CH(CH 3 )-;
- L is -C(O)N(R 7 )-; and
- R 7 and R A are as defined in formula (11).
- the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier.
- the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of 2-(l- ⁇ [(3-methylbenzoyl)amino]methyl ⁇ -4-piperidinyl)pyridimum N-oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier.
- the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a phosphodiesterase 5 inhibitor.
- the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of 2-(l- ⁇ [(3-methylbenzoyl)amino]methyl ⁇ -4-piperidinyl)pyridinium N-oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a phosphodiesterase 5 inhibitor.
- the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with an adrenergic receptor antagonist.
- the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of 2-(l- ⁇ [(3-methylbenzoyl)amino]methyl ⁇ -4-piperidinyl)pyridimum N-oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with an adrenergic receptor antagonist.
- the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a dopamine agonist.
- the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of 2-(l- ⁇ [(3-methylbenzoyl)ammo]methyl ⁇ -4-piperidinyl)pyridinium N-oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a dopamine agonist.
- the present invention relates to method of treating male erectile dysfunction in a male human comprising administering to the male human in need of such treatment a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier.
- the present invention relates to method of treating male erectile dysfunction in a male human comprising administering to the male human in need of such treatment a therapeutically effective amount of 2-(l- ⁇ [(3- methylbenzoyl)amino]methyl ⁇ -4-piperidinyl)pyridinium N-oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier.
- the present invention relates to method of treating male erectile dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a phosphodiesterase 5 inhibitor.
- the present invention relates to method of treating male erectile dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of 2-(l- ⁇ [(3-methylbenzoyl)amino]methyl ⁇ -4-piperidinyl)pyridinium N- oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a phosphodiesterase 5 inhibitor.
- the present invention relates to method of treating male erectile dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with an adrenergic receptor antagonist.
- the present invention relates to method of treating male erectile dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of 2-(l- ⁇ [(3-methylbenzoyl)amino]methyl ⁇ -4-piperidinyl)pyridinium N- oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with an adrenergic receptor antagonist.
- the present invention relates to method of treating male erectile dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a dopamine agonist.
- the present invention relates to method of treating male erectile dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of 2-(l- ⁇ [(3-methylbenzoyl)amino]methyl ⁇ -4-piperidinyl)pyridinium N- oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a dopamine agonist.
- the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier.
- the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of 2-(l- ⁇ [(3-methylbenzoyl)amino]methyl ⁇ -4- piperidinyl)pyridinium N-oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier.
- the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a phosphodiesterase 5 inhibitor.
- the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of 2-(l- ⁇ [(3-methylbenzoyl)amino]methyl ⁇ -4-piperidinyl)pyridir_ium N- oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a phosphodiesterase 5 inhibitor.
- the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with an adrenergic receptor antagonist.
- the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of 2-(l- ⁇ [(3-methylbenzoyl)amino]methyl ⁇ -4-piperidinyl)pyridinium N- oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with an adrenergic receptor antagonist.
- the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a dopamine agonist.
- the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of 2-(l- ⁇ [(3-methylbenzoyl)ammo]methyl ⁇ -4-piperidinyl)pyridinium N- oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a dopamine agonist.
- the present invention relates to method of treating a disorder wherein the disorder is cardiovascular disorders, inflammatory disorders, attention deficit hyperactivity disorder, Alzheimer's disease, drug abuse, Parkinson's disease, schizophrenia, anxiety, mood disorders or depression in a mammal comprising administering to the mammal in need of such freatment a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.
- the present invention relates to method of treating a disorder wherein the disorder is cardiovascular disorders, inflammatory disorders, attention deficit hyperactivity disorder, Alzheimer's disease, drug abuse, Parkinson's disease, schizophrenia, anxiety, mood disorders or depression in a mammal comprising administering to the mammal in need of such freatment a therapeutically effective amount of 2-(l- ⁇ [(3- methylbenzoyl)amino]methyl ⁇ -4-piperidinyl)pyridinium N-oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.
- the present invention relates to compounds of formula (III)
- Xi is a bond or CR B RC!
- X 2 is a bond or CRDRE . provided that when Xi is a bond, then X 2 is C D E; further provided that when X 2 is bond, then Xi is CR ⁇ Rc;
- A is aryl, arylalkyl, cycloalkyl, or cycloalkylalkyl;
- L is -N(R 7 )C(O)-, -C(O)N(R 7 )-, -N(R 7 )C(S)-, or -C(S)N(R 7 )- wherein the left end of the -N(R 7 )C(O)-, -C(O)N(R 7 )-, -N(R 7 )C(S)-, and -C(S)N(R 7 )- is attached to A and the right end is attached to D;
- L 2 is a bond or alkylene
- D is alkylene, fluoroalkylene, or hydroxyalkylene
- RA, RB, R C , RD, and R E are independently hydrogen or alkyl
- Ri, R 2 , R 3 , and R 4 are each independently hydrogen, alkoxy, alkenyl, alkyl, alkylsulfmyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, -NZ ⁇ Z 2 , (NZ 3 Z 4 )alkyl, (NZ 3 Z 4 )carbonyl, or (NZ 3 Z 4 )sulfonyl;
- Zi and Z 2 are each independently hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, arylalkyl, arylalkylsulfonyl, arylsulfonyl, or formyl;
- Z 3 and Z are each independently hydrogen, alkyl, aryl, or arylalkyl
- X is N(Re), O, or S
- Y is C(R 4 ) or ;
- R 6 is hydrogen or alkyl
- R 7 is hydrogen or alkyl.
- the present invention relates to compounds of formula (III) wherein A is aryl; B is
- X ⁇ is CR ⁇ Rc .
- ⁇ 2 is CR D R E ;
- L is -N(R 7 )C(O)-; and
- R A , R B , R C , R D , and R E are as defined in formula (III).
- the present invention relates to compounds of formula (III) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents indpendently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ;
- B is Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ Z 4 )alkyl, or
- R 2 and R A are hydrogen; R 3 is hydrogen or hydroxy; Xi is CR B Rc; X 2 is CRDRE; D is -CH 2 -; L 2 is a bond; and L is -N(R 7 )C(O)-; and R A , R B , Re, RD, RE, RI, R2, R3, R_ t , and R 7 are as defined in formula (III).
- the present invention relates to compounds of formula (III) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nifro, phenyl, or -NZ]Z 2 ; B is
- R 2 and R 4 are hydrogen; R 3 is hydrogen or hydroxy;
- X] is CR B Rc;
- X 2 is CR D R E.
- D is -CH -;
- L 2 is a bond;
- L is -N(R 7 )C(O)-; and
- RA, R B , RC, R D , R E , and R are hydrogen.
- the present invention relates to compounds of formula (III) wherein A is heterocycle; B is
- X ! is CR B R C.
- X2 is CR D R E ;
- L is -N(R 7 )C(O)-; and D, L 2 , X, Y, R A , R B , Rc, R D ,
- R E , R 2 , R 3 , and R 7 are as defined in formula (III).
- the present invention relates to compounds of formula (III) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl,
- R 2 and R 3 are hydrogen; Xi is CR B Rc; X 2 is CR D R E ; X is N(R 6 ), O, or S; Y is N; D is -CH 2 -; L 2 is a bond; L is -N(R 7 )C(O)-; and R A , R B , Rc, RD, RE, R2, R3, and R 7 are hydrogen; and R 6 is hydrogen or alkyl wherein a prefened alkyl is methyl.
- the present invention relates to compounds of formula (III) wherein A is heterocycle wherein the heterocycle is benzimidazolyl substituted with 1 alkyl substitutuent wherein a prefened alkyl substituent is methyl; B is
- X is CR B Rc
- X2 is CR D R E
- X is N(R 6 ), 0, or S
- Y is
- the present invention relates to compounds of formula (III) wherein A is aryl; B is
- the present invention relates to compounds of formula (III) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nifro, phenyl, or -NZjZ 2 ; B is
- R ⁇ is hydrogen, alkyl, cyano, haloalkyl, halogen, nifro, (NZ 3 Z 4 )alkyl, or
- R 2 and R A are hydrogen; R 3 is hydrogen or hydroxy; Xi is a bond; X 2 is CRDR E ; D is -CH 2 -; L 2 is a bond; L is -N(R 7 )C(O)-; and R 7 , R A , R D , and R E are as defined in formula (III).
- the present invention relates to compounds of formula (III) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nifro, phenyl, or -NZjZ 2 ; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z 4 )carbonyl;
- R 2 and R 4 are hydrogen;
- R 3 is hydrogen or hydroxy;
- Xi is a bond;
- X 2 is C D R E ;
- D is -CH2-;
- L 2 is a bond;
- L is -N(R 7 )C(O)-;
- R 7 , RA, R D , and RE are hydrogen.
- the present invention relates to compounds of formula (III) wherein A is heterocycle;
- B is
- R 3 , and R 7 are as defined in formula (III).
- the present invention relates to compounds of formula (III) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl, wherein the heterocycle is substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
- B is
- R 2 and R 3 are hydrogen; X! is a bond; X 2 is CR D R E ; X is N(R 6 ), O, or S; Y is N; D is -CH 2 -; L 2 is a bond; L is -N(R 7 )C(O)-; and R 6 , R A , R D , R E , and R 7 are as defined in formula (III).
- the present invention relates to compounds of formula (111) wherein A is heterocycle wherein the heterocycle is benzimidazolyl substituted with 1 alkyl substitutuent wherein a prefened alkyl substituent is methyl; B is
- R 2 and R 3 are hydrogen; X] is a bond; X 2 is CR D R E ; X is N(R 6 ), O, or S; Y is
- the present invention relates to compounds of formula (III) wherein A is aryl; B is X 2 is CR D R E ; L is -N(R 7 )C(O)-; and D, L 2 , X, Y, R A , R D , R E , 2 , R 3 , and R 7 are as defined in formula (III).
- the present invention relates to compounds of formula (III) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nifro, phenyl, or -NZ ⁇ Z 2 ; B is
- R 2 and R 3 are hydrogen; Xi is a bond; X 2 is CR D RE; X is N(Re), O, or S; Y is C(R- ; D is -CH 2 -; L 2 is a bond; L is -N(R )C(O)-; * is hydrogen, alkyl, or cyano; and R ⁇ , R A , R D , R E , R A , and R 7 are as defined in formula (III).
- the present invention relates to compounds of formula (III) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nifro, phenyl, or -NZ]Z 2 ; B is
- R 2 and R 3 are hydrogen; X! is a bond; X 2 is CR D R E ; X is N(R 6 ), O, or S; Y is
- R E , R A , and R 7 are hydrogen; and Re is hydrogen or alkyl wherein a prefened alkyl is methyl.
- the present invention relates to compounds of formula (III) wherein A is aryl; B is
- Xj is CRBRC; X2 is a bond; L is -N(R 7 )C(O)-; and L 2 , D, R h R 2 , R 3 , R 4 , R 5 ,
- R 7 , R A , R B , and Rc are as defined in formula (III).
- the present invention relates to compounds of formula (III) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is Ri, R 2 , R 3 , RA, and R 5 are hydrogen; Xi is CRBRC; X 2 is a bond; D is -CH 2 -;
- L 2 is -CH 2 -; L is -N(R 7 )C(O)-; and R B , Rc, and R 7 are as defined in formula (III).
- the present invention relates to compounds of formula (III) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
- Ri, R 2 , R 3 , RA, and R 5 are hydrogen; Xi is CR B Rc; X 2 is a bond; D is -CH 2 -;
- L 2 is -CH 2 -; L is -N(R )C(O)-; and R B , Rc and R 7 are hydrogen.
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to said mammal in need of such freatment a therapeutically effective amount of a compound of formula (IV)
- Xi is a bond or CRBRC
- X 2 is a bond or CRDRE; provided that when Xi is a bond, then X 2 is CRDRE; further provided that when X 2 is bond, then Xi is CRBRC;
- A is aryl, arylalkyl, cycloalkyl, or cycloalkylalkyl;
- Li is -N(R 7 )C(O)-, -C(O)N(R 7 )-, -N(R 7 )C(S)-, or -C(S)N(R 7 )- wherein the left end of the -N(R 7 )C(O)-, -C(O)N(R 7 )-, -N(R 7 )C(S)-, and -C(S)N(R 7 )- is attached to A and the right end is attached to D;
- L 2 is a bond or alkylene
- D is alkylene, fluoroalkylene, or hydroxyalkylene
- R A , RB, Rc, RD, and R E are independently hydrogen or alkyl
- Ri, R 2 , R 3 , and R 4 are each independently hydrogen, alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, -NZ ⁇ Z 2 , (NZ 3 Z 4 )alkyl, (NZ 3 Z 4 )carbonyl, or (NZ 3 Z )sulfonyl;
- Zi and Z 2 are each independently hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, arylalkyl, arylalkylsulfonyl, arylsulfonyl, or formyl;
- Z 3 and Z are each independently hydrogen, alkyl, aryl, or arylalkyl
- X is N(Re), O, or S
- Y is C(R 4 ) orN
- R 6 is hydrogen or alkyl
- R 7 is hydrogen or alkyl.
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is aryl; B is
- X 2 is CR D R E ;
- L is -N(R 7 )C(O)-;
- L 2 , D, R R 2 , R 3 , R A , R 7 , R A , R B , R C , RD, and RE are as defined in formula (IV).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
- R 2 and R 4 are hydrogen; R 3 is hydrogen or hydroxy; Xi is CR B R C ; X2 is CR D RE; D is -CH 2 -; L 2 is a bond; L is -N(R 7 )C(O)-; and R 7 , R A , R B , Re, RD, and R E are as defined in formula (IV).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nifro, phenyl, or -NZ ⁇ Z 2 ; B is
- R ⁇ is hydrogen, alkyl, cyano, haloalkyl, halogen, nifro, (NZ 3 Z )alkyl, or
- (NZ 3 Z 4 )carbonyl; R 2 and R 4 are hydrogen; R 3 is hydrogen or hydroxy; X] is CR B Rc; X 2 is CR D R E ; D is -CH 2 -; L 2 is a bond; L is -N(R 7 )C(O)-; and R 7 , R A , R B , Rc, R D , and R E are hydrogen.
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is heterocycle; B is
- RE, R 2 , R 3 , and R are as defined in formula (IV).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl, wherein the heterocycle is substituted with 0, 1 , 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nifro; B is
- R 2 and R 3 are hydrogen; Xi is CR B Rc; X 2 is CR D R E ; X is N(R 6 ), O, or S; Y is N; D is -CH 2 -; L 2 is a bond; L is -N(R 7 )C(O)-; and Rg, RA, R B , R C , R D , R E , and R are as defined in formula (IV).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IN) wherein A is heterocycle wherein the heterocycle is benzimidazolyl substituted with 1 alkyl substitutuent wherein a prefened alkyl substituent is methyl; B is
- R 2 and R 3 are hydrogen; Xi is CR B Rc; 2 is CR D R E ; X is N(R 6 ), O, or S; Y is
- D is -CH 2 -;
- L 2 is a bond;
- L is - ⁇ (R 7 )C(O)-; and
- R A , R B , Rc, R D , R E , and R 7 are hydrogen; and
- Re is hydrogen or alkyl wherein a prefened alkyl is methyl.
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is aryl; B is
- ⁇ 2 is CR D R E ;
- L is -N(R 7 )C(O)-; and
- L 2 , D, R h R 2 , R 3 , R 4 , R 7 , R A , R D , and R E are as defined in formula (IV).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nifro, (NZ 3 Z )alkyl, or
- CRDRE CRDRE
- D is -CH 2 -
- L 2 is a bond
- L is -N(R 7 )C(O)-
- R 7 , R A , RD, and R E are as defined in formula (IN).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or - ⁇ Z ⁇ Z 2 ; B is
- R 2 and R 4 are hydrogen;
- R 3 is hydrogen or hydroxy;
- Xi is a bond;
- X 2 is CR D R E ;
- D is -CH 2 -;
- L 2 is a bond;
- L is -N(R )C(O)-;
- R 7 , R A , R D , and R E are hydrogen.
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is heterocycle; B is
- Xi is a bond
- X 2 is CR D RE
- L is -N(R 7 )C(O)-
- R 3 , and R 7 are as defined in formula (IV).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, py olyl, 1,3-thiazolyl, or thienyl, wherein the heterocycle is substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is R 2 and R 3 are hydrogen; Xi is a bond; X 2 is CR D R E ; X is N(R 6 ), O, or S;
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is heterocycle wherein the heterocycle is benzimidazolyl substituted with 1 alkyl substitutuent wherein a prefened alkyl substituent is methyl; B is
- R 2 and R 3 are hydrogen; Xi is a bond; X 2 is CR D R E ; X is N(R 6 ), O, or S; Y is N; D is -CH 2 -; L 2 is a bond; L is -N(R 7 )C(O)-; RA, RD, RE, and R are hydrogen; and Re is hydrogen or alkyl wherein a prefened alkyl is methyl.
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is aryl; B is
- Xi is a bond
- X 2 is CR D R E
- L is -N(R 7 )C(O)-
- D, L 2 , X, Y, R A , R D , RE, R 2 , R 3 , and R 7 are as defined in formula (IV).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (TV) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- R 2 and R 3 are hydrogen; Xi is a bond; X 2 is CR D R E ; X is N(R 6 ), O, or S; Y is
- R 4 C(R 4 ); D is -CH 2 -; L 2 is a bond; L is -N(R 7 )C(O)-; R A is hydrogen, alkyl, or cyano; and R5, R A , R D , R E , and R 7 are as defined in formula (IV).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZjZ 2 ; B is
- R 2 and R 3 are hydrogen; X] is a bond; X 2 is CRDRE; X is N(R 6 ), O, or S; Y is
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is aryl; B is
- X ! is CR B Rc; X 2 is a bond; L is -N(R 7 )C(O)-; and L 2 , D, R R 2 , R 3 , ;, R 5 ,
- R 7 , RA, RB, and Rc are as defined in formula (TV).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nifro, phenyl, or -NZ ⁇ Z 2 ; B is
- Ri, R 2 , R 3 , ⁇ , and R 5 are hydrogen; Xi is CRBR C ; X 2 is a bond; D is -CH 2 -;
- L 2 is -CH 2 -; L is -N(R )C(O)-; and R B , Rc, and R 7 are as defined in formula (IV).
- the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
- R 1; R 2 , R 3 , , and R 5 are hydrogen; Xi is CR B R C ; X 2 is a bond; D is -CH 2 -;
- L 2 is -CH 2 -; L is -N(R 7 )C(O)-; and R B , Rc, and R 7 are hydrogen.
- the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IN) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier.
- the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IN) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a phosphodiesterase 5 inhibitor.
- the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (TV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with an adrenergic receptor antagonist.
- a compound of formula (TV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with an adrenergic receptor antagonist.
- the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a dopamine agonist.
- the present invention relates to method of treating male erectile dysfunction in a male human comprising administering to the male human in need of such freatment a therapeutically effective amount of a compound of formula (TV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier.
- a compound of formula (TV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier.
- the present invention relates to method of treating male erectile dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a phosphodiesterase 5 inhibitor.
- the present invention relates to method of treating male erectile dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with an adrenergic receptor antagonist.
- the present invention relates to method of treating male erectile dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a dopamine agonist.
- the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of formula (IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier.
- the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a phosphodiesterase 5 inhibitor.
- the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (TV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with an adrenergic receptor antagonist.
- a compound of formula (TV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with an adrenergic receptor antagonist.
- the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a dopamine agonist.
- the present invention relates to method of treating a disorder wherein the disorder is cardiovascular disorders, inflammatory disorders, attention deficit hyperactivity disorder, Alzheimer's disease, drug abuse, Parkinson's disease, schizophrenia, anxiety, mood disorders or depression in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of formula (TV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.
- a compound of formula (TV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.
- alkenyl as used herein, means a straight or branched chain hydrocarbon containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens.
- Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5- hexenyl, 2-heptenyl, 2-methyl-l-heptenyl, and 3-decenyl.
- alkoxy as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
- Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.
- alkoxycarbonyl as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
- Representative examples of alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, and tert-butoxycarbonyl.
- alkoxysulfonyl as used herein, means an alkoxy group, as defined herein, appended appended to the parent molecular moiety through a sulfonyl group, as defined herein.
- Representative examples of alkoxysulfonyl include, but are not limited to, methoxysulfonyl, ethoxysulfonyl and propoxysulfonyl.
- alkyl as used herein, means a straight or branched chain hydrocarbon containing from 1 to 10 carbon atoms.
- Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n- pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl.
- alkylcarbonyl as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
- Representative examples of alkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl, 2,2-dimethyl- 1-oxopropyl, 1-oxobutyl, and 1-oxopentyl.
- alkylcarbonyloxy means an alkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
- Representative examples of alkylcarbonyloxy include, but are not limited to, acetyloxy, ethylcarbonyloxy, and tert-butylcarbonyloxy.
- alkylene means a divalent group derived from a straight or branched chain hydrocarbon of from 1 to 10 carbon atoms. Examples are -CH 2 -, -CH 2 CH 2 -, -CH(CH 3 )-, -CH(CH 2 CH 3 )-, -CH 2 CH 2 CH 2 -, and -CH 2 CH 2 CH 2 CH 2 -.
- alkylsulfinyl as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfinyl group, as defined herein.
- Representative examples of alkylsulfinyl include, but are not limited to, methylsulfinyl and ethylsulfinyl.
- alkylsulfonyl as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
- Representative examples of alkylsulfonyl include, but are not limited to, methylsulfonyl and ethylsulfonyl.
- alkylthio as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfur atom.
- Representative examples of alkylthio include, but are not limited, methylsulfanyl, ethylsulfanyl, tert-butylsulfanyl, and hexylsulfanyl.
- alkynyl as used herein, means a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond.
- Representative examples of alkynyl include, but are not limited, to acetylenyl, 1- propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.
- aryl as used herein, means a phenyl group, or a bicyclic fused ring system, or a tricyclic fused ring system wherein one or more of the fused rings is a phenyl group.
- Bicyclic fused ring systems are exemplified by a phenyl group fused to another phenyl group or fused to a cycloalkyl group wherein the cycloalkyl group is selected from cyclopentane, cycloahexane, cycloheptane, or cyclooctane.
- Tricyclic fused ring systems are exemplified by a bicyclic fused ring system fused to a phenyl group.
- aryl include, but are not limited to, anthracenyl, azulenyl, fluorenyl, 5,6,7,8- tefrahydronaphthalenyl, 5,6,7,8-tefrahydro-l-naphthalenyl, 1,2,3,4-tetrahydro-l-naphthalenyl, ( 1 S)- 1 ,2,3 ,4-tetrahydro- 1 -naphthalenyl, ( 1 R)- 1 ,2,3 ,4-tefrahydro- 1 -naphthalenyl, indanyl, indenyl, ,3-dihydro-lH-indenyl, 2,3-dihydro-lH-inden-5-yl, 1-naphthyl, 2-naphthyl, and phenyl.
- the aryl groups of the present invention are substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, methylenedioxy, nifro, - NZ ⁇ Z 2 , (NZ 3 Z 4 )carbonyl, and (NZ 3 Z 4 )sulfonyl.
- substituents independently selected from alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkyl
- the aryl groups of this invention can be further substituted with an additional aryl or arylalkyl group, as defined herein, wherein the additional aryl group or the aryl portion of arylalkyl group are substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, methylenedioxy, nifro, - NZ ⁇ Z 2 , (NZ 3 Z 4 )carbonyl, and (NZ 3 Z 4 )sulfonyl.
- substituents independently selected from alkoxy, alkenyl, alkyl, alkyl
- Representative examples include, but are not limited to, l,3-benzodioxol-5-yl, 3-benzylphenyl, l,l'-biphenyl-3yl, 2-bromophenyl, 3- bromophenyl, 4-bromophenyl, 4-bromo-3-methylphenyl, 4-bromo-2-methylphenyl, 2- chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3-chloro-4-fluorophenyl, 4-chloro-3- methoxyphenyl, 3-chloro-2-methylphenyl, 2-chloro-5-methylphenyl, 2-chloro-6- methylphenyl, 4-chloro-2,6-dimethylphenyl, 3-chloro-4-fluorophenyl, 5-chloro-2- methylphenyl, 4-chloro-3-methylphenyl, 3-chloro-4-methylphenyl, 2-chloro-5- trifluoromethylphen
- arylalkyl as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
- Representative examples of arylalkyl include, but are not limited to, phenylmethyl, 2-phenylethyl, 3- phenylpropyl, and 3-(2-methylphenyl)propyl.
- arylsulfonyl as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
- Representative examples of arylsulfonyl include, but are not limited to, phenylsulfonyl, 2- methylphenylsulfonyl, 2-nitrophenylsulfonyl, and 3-nitrophenylsulfonyl.
- arylalkylsulfonyl as used herein, means an arylalkyl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
- Representative examples of arylalkylsulfonyl include, but are not limited to, (phenylmethyl)sulfonyl, (2-phenylethyl)sulfonyl, and (3-phenylpropyl)sulfonyl.
- carbonyl as used herein, means a -C(O)- group.
- cyano as used herein, means a -CN group.
- cycloalkyl as used herein, means a monocyclic, bicyclic, or tricyclic ring system.
- Monocyclic ring systems are exemplified by a saturated cyclic hydrocarbon group containing from 3 to 8 carbon atoms. Examples of monocyclic ring systems include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
- Bicyclic ring systems are exemplified by a bridged monocyclic ring system in which two non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge of between one and three additional carbon atoms (-CH 2 -, -CH 2 CH 2 -, and -CH 2 CH 2 CH 2 -).
- Representative examples of bicyclic ring systems include, but are not limited to, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, and bicyclo[4.2.1]nonane.
- Tricyclic ring systems are exemplified by a bicyclic ring system in which two non-adjacent carbon atoms of the bicyclic ring are linked by a bond or an alkylene bridge of between one and three carbon atoms (-CH 2 -, -CH 2 CH 2 -, and -CH 2 CH 2 CH 2 -).
- Representative examples of tricyclic-ring systems include, but are not limited to, tricyclo[3.3.1.0 3,7 ]nonane and tricyclo[3.3.1.1 3 ' 7 ]decane (adamantyl).
- cycloalkyl groups of the present invention are substituted with 0, 1, 2, 3, or 4 substituents independently selected from alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nifro, -NZ ⁇ Z 2 , (NZ 3 Z 4 )carbonyl or (NZ 3 Z 4 )sulfonyl.
- substituents independently selected from alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carb
- fluoroalkylene means at least one fluoride atom (-F) is appended to the parent molecular moiety through an alkylene group, as defined herein.
- fluoroalkylene are -CH(F)-, -CH(F)CH 2 -, -C(F) 2 CH 2 -, -CH(F)CH(F)-, -CH(CF 3 )-, -CH(CH 2 CF 3 )-, and -CH 2 CH 2 CH 2 CH(F)-.
- halo or halogen as used herein, refers to -CI, -Br, -I or -F.
- haloalkoxy means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
- Representative examples of haloalkoxy include, but are not limited to, 2-fluoro-l- chloroethoxy, chloromethoxy, 2-fluoroethoxy, frifluoromethoxy, and pentafluoroethoxy.
- haloalkyl as used herein, means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
- Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2- fluoroethyl, trifluoromethyl, pentafluoroethyl, and 2-chloro-3-fTuoropentyl.
- heterocycle or “heterocyclic” as used herein, means a monocyclic, bicyclic, or tricyclic ring system.
- Monocyclic ring systems are exemplified by any 3- or 4- membered ring containing a heteroatom independently selected from oxygen, nitrogen and sulfur; or a 5-, 6- or 7-membered ring containing one, two or three heteroatoms wherein the heteroatoms are independently selected from nitrogen, oxygen and sulfur.
- the 5-membered ring has from 0-2 double bonds and the 6- and 7-membered ring have from 0-3 double bonds.
- monocyclic ring systems include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepinyl, 1,3-dioxolanyl, dioxanyl, dithianyl, furyl, imidazolyl, imidazolinyl, imidazolidinyl, isothiazolyl, isothiazolinyl, isothiazolidinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolyl, oxadiazolinyl, oxadiazolidinyl, oxazolyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridinyl,
- Bicyclic ring systems are exemplified by any of the above monocyclic ring systems fused to a phenyl group, a cyclohexyl group, a cyclopentyl group, or another monocyclic heterocycle.
- Representative examples of bicyclic ring systems include but are not limited to, for example, benzimidazolyl, benzodioxinyl, benzothiazolyl, benzothienyl, benzotriazolyl, benzoxazolyl, benzofuranyl, benzopyranyl, benzothiopyranyl, cinnolinyl, indazolyl, indolyl, 2,3-dihydroindolyl, indolizinyl, naphthyridinyl, isobenzofuranyl, isobenzothienyl, isoindolyl, isoquinolinyl, phthalazinyl, pyranopyridinyl, quinolinyl,
- Tricyclic rings systems are exemplified by any of the above bicyclic ring systems fused to a phenyl group, a cyclohexyl group, a cyclopentyl group, or another monocyclic heterocycle.
- Representative examples of tricyclic ring systems include, but are not limited to, acridinyl, carbazolyl, carbolinyl, dibenzo[b,d]fixranyl, dibenzo[b,d]thienyl, naphtho[2,3-b]furan, naphtho[2,3-b]thienyl, phenazinyl, phenothiazinyl, phenoxazinyl, thianthrenyl, thioxanthenyl and xanthenyl.
- heterocycles of this invention are substituted with 0, 1, 2,or 3 substituents independently selected from alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, -NZ ⁇ Z 2 , (NZ 3 Z )carbonyl, and (NZ 3 Z 4 ) sulfonyl.
- heterocycle groups of this invention can be further substituted with an additional heterocycle group, as defined herein, wherein the additional heterocycle group is substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, -NZ ⁇ Z 2 , (NZ 3 Z 4 )carbonyl, and (NZ 3 Z )sulfonyl.
- substituents independently selected from alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl,
- heterocyclealkyl means a heterocycle, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
- heterocyclealkyl include, but are not limited to, pyridin-3- ylmethyl, 2-pyrimidin-2-ylpropyl, and 4-pyridin-2-ylpiperazin-l-ylmethyl.
- heterocyclecarbonyl means a heterocycle, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
- Representative examples of heterocyclecarbonyl include, but are not limited to, pyridin-3- ylcarbonyl, quinolin-3-ylcarbonyl, and 4-pyridin-2-ylpiperazin-l-ylmethylcarbonyl.
- hydroxy as used herein, means an -OH group.
- hydroxyalkyl as used herein, means at least one hydroxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
- Representative examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2- hydroxyethyl, 3-hydroxypropyl 2-ethyl-4-hydroxyheptyl and 2,4-dihydroxybutyl.
- hydroxyalkylene as used herein, means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through an alkylene group, as defined herein.
- Representative examples of hydroxyalkylene are -CH 2 CH(OH)CH 2 -, -CH(CH 2 OH)-, -CH(CH 2 CH 2 OH)-, and -CH 2 CH 2 CH(OH)CH 2 -.
- mercapto as used herein, means a -SH group.
- methylenedioxy as used herein, means a -OCH 2 O- group wherein the oxygen atoms of the methylenedioxy are attached to the parent molecular moiety through two adjacent carbon atoms.
- a representative example includes, but is not limited to, 1,3- benzodioxol-5-yl.
- nitro as used herein, means a - O 2 group.
- nitrogen protecting group means those groups intended to protect an amino group against undesirable reactions during synthetic procedures. Nitrogen protecting groups comprise carbamates, amides, N-benzyl derivatives, and imine derivatives. Prefened nitrogen protecting groups are acetyl, benzoyl, benzyl, benzyloxycarbonyl (Cbz), formyl, phenylsulfonyl, pivaloyl, tert-butoxycarbonyl (Boc), tert-butylacetyl, trifluoroacetyl, and triphenylmethyl (trityl).
- Zi and Z 2 are each independently selected from hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, arylalkyl, arylalkylsulfonyl, arylsulfonyl, formyl, heterocycle, heterocyclealkyl, and heterocyclealkylcarbonyl.
- Representative examples of -NZ ⁇ Z 2 include, but are not limited to, amino, methylamino, dimethylamino, acetylamino, (acetyl)(methyl)amino, and (methylsulfonyl)amino.
- -NZ 3 Z 4 means two groups, Z 3 and Z , which are appended to the parent molecular moiety through a nitrogen atom.
- Z 3 and Z 4 are each independently selected from hydrogen, alkyl, aryl, or arylalkyl.
- Representative examples of -NZ 3 Z include, but are not limited to, amino, methylamino, dimethylamino, ethylmethylamino, phenylamino, (phenylmethyl)amino, (2-phenylethyl)amino, (phenyl)(methyl)amino, and diethylamino.
- (NZ 3 Z )alkyl as used herein, means a -NZ 3 Z 4 group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
- Representative examples of (NZ 3 Z 4 )alkyl include, but are not limited to, aminomethyl, (dimethylamino)methyl, and (mefhylamino)methyl.
- (NZ 3 Z 4 )carbonyl means a -NZ 3 Z 4 group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
- Representative examples of (NZ 3 Z 4 )carbonyl include, but are not limited to, aminocarbonyl, (methylamino)carbonyl, (dimethylamino)carbonyl, (phenylmethylamino)carbonyl, ((phenyl)(methyl)amino)carbonyl, (phenylamino)carbonyl, (ethylmethylamino)carbonyl, and (diethylamino)carbonyl.
- (NZ 3 Z 4 )sulfonyl as used herein, means a -NZ 3 Z 4 group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
- (NZ 3 Z 4 )sulfonyl include, but are not limited to, aminosulfonyl, (methylamino)sulfonyl, (dimethylamino)sulfonyl, (phenylmethylamino)sulfonyl, ((phenylmethyl)(methyl)amino)sulfonyl, (phenylmethylamino)sulfonyl, (phenylamino)sulfonyl, and (ethylmethylamino)sulfonyl.
- sulfinyl as used herein, means a -S(O)- group.
- sulfonyl as used herein, means a -S(O) 2 - group.
- sexual dysfunction means sexual dysfunction in mammals including human male and human female sexual dysfunction.
- male sexual dysfunction includes, but is not limited to, male erectile dysfunction or premature ejacualtion.
- female sexual dysfunction as used herein includes, but is not limited to, female anorgasmia, clitoral erectile insufficiency, vaginal engorgement, dyspareunia, or vaginismus.
- Stereoisomers may exist as stereoisomers wherein, asymmetric or chiral centers are present. These stereoisomers are “R” or “S” depending on the configuration of substituents around the chiral carbon atom.
- R and “S” used herein are configurations as defined in IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem., 1976, 45: 13-30.
- Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers.
- stereochemistry at the point of attachment of -L 2 -B of compounds of formula (III) or formula (IV) wherein Xi is a bond and X 2 is CR D R E may independently be either (R) or (S).
- the stereochemistry at the point of attachment of -L 2 -B of compounds of formula (III) or formula (TV) wherein Xj is CR ⁇ Rc and X 2 is a bond may independently be either (R) or (S).
- the stereochemistry at the point of attachment of -L 2 -B of compounds of formula (III) or formula (IN) wherein Xi is CR B Rc and X 2 is CR D R E may independently be either (R) or (S).
- Individual stereoisomers of compounds of the present invention may be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of racemic mixtures followed by resolution well-known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) direct separation of the mixture of optical enantiomers on chiral chromatographic columns, or (3) formation of a diastereomeric salt followed by selective recrystallization of one of the diastereomeric salts.
- Prefened compounds of the present invention include:
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US154373 | 1998-09-16 | ||
US10/154,373 US20030232836A1 (en) | 2002-05-23 | 2002-05-23 | Acetamides and benzamides that are useful in treating sexual dysfunction |
US425152 | 2003-04-29 | ||
US10/425,152 US20040029887A1 (en) | 2002-05-23 | 2003-04-29 | Acetamides and benzamides that are useful in treating sexual dysfunction |
PCT/US2003/015868 WO2003099266A2 (fr) | 2002-05-23 | 2003-05-19 | Acetamides et benzamides utilises dans le traitement d'une dysfonction sexuelle |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1509213A2 true EP1509213A2 (fr) | 2005-03-02 |
Family
ID=52340037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03755402A Withdrawn EP1509213A2 (fr) | 2002-05-23 | 2003-05-19 | Acetamides et benzamides utilises dans le traitement d'une dysfonction sexuelle |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1509213A2 (fr) |
JP (1) | JP2005531571A (fr) |
AU (1) | AU2003231801A1 (fr) |
BR (1) | BR0306625A (fr) |
CA (1) | CA2486564A1 (fr) |
MX (1) | MXPA04011621A (fr) |
TW (1) | TW200404539A (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4866610B2 (ja) * | 2003-08-18 | 2012-02-01 | 富士フイルムファインケミカルズ株式会社 | ピリジルテトラヒドロピリジン類およびピリジルピペリジン類 |
US8536176B2 (en) * | 2008-08-01 | 2013-09-17 | Nippon Chemiphar Co., Ltd. | GPR119 agonist |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA825719B (en) * | 1981-09-03 | 1983-06-29 | Recordati Chem Pharm | Alkanoylanilides |
JPS6147466A (ja) * | 1984-08-10 | 1986-03-07 | Dainippon Pharmaceut Co Ltd | アミン誘導体 |
FR2573075B1 (fr) * | 1984-09-14 | 1987-03-20 | Innothera Lab Sa | Nouvelles (pyridyl-2)-1 piperazines, leur procede de preparation et leur application en therapeutique |
CA1340113C (fr) * | 1988-05-24 | 1998-11-03 | Magid A. Abou-Gharbia | Carboxaamides aryl -et heteroarylpiperazinyliques exercant un effet sur le systeme nerveux central |
US5395835A (en) * | 1994-03-24 | 1995-03-07 | Warner-Lambert Company | Naphthalamides as central nervous system agents |
FR2742149B1 (fr) * | 1995-12-11 | 1998-02-13 | Inst Nat Sante Rech Med | Nouveaux derives de 2-naphtamides et leurs applications therapeutiques |
US5932538A (en) * | 1996-02-02 | 1999-08-03 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
CA2253862A1 (fr) * | 1996-05-16 | 1997-11-20 | Wai C. Wong | Dihydropyrimidines et leurs emplois |
WO1998037893A1 (fr) * | 1997-02-26 | 1998-09-03 | Sumitomo Pharmaceuticals Co., Ltd. | Antagoniste du recepteur dopaminergique d4 |
EP1177172A1 (fr) * | 1999-05-05 | 2002-02-06 | Ortho-McNeil Pharmaceutical, Inc. | LIGANDS DE RECEPTEURS DU NEUROPEPTIDE Y DERIVES DE 3a,4,5,9b-TETRAHYDRO-1H-BENZ e]INDOL-2-YL AMINE, UTILISES POUR LE TRAITEMENT DE L'OBESITE ET D'AUTRES ETATS PATHOLOGIQUES |
NZ516782A (en) * | 1999-07-28 | 2004-12-24 | Ortho Mcneil Pharm Inc | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders |
PL365890A1 (en) * | 2000-11-22 | 2005-01-10 | Abbott Laboratories | The use of selective dopamine d4 receptor agonists for treating sexual dysfunction |
GB0209715D0 (en) * | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
-
2003
- 2003-05-19 EP EP03755402A patent/EP1509213A2/fr not_active Withdrawn
- 2003-05-19 MX MXPA04011621A patent/MXPA04011621A/es unknown
- 2003-05-19 BR BRPI0306625-8A patent/BR0306625A/pt not_active IP Right Cessation
- 2003-05-19 JP JP2004506790A patent/JP2005531571A/ja active Pending
- 2003-05-19 AU AU2003231801A patent/AU2003231801A1/en not_active Abandoned
- 2003-05-19 CA CA002486564A patent/CA2486564A1/fr not_active Abandoned
- 2003-05-23 TW TW092114035A patent/TW200404539A/zh unknown
Non-Patent Citations (1)
Title |
---|
See references of WO03099266A2 * |
Also Published As
Publication number | Publication date |
---|---|
AU2003231801A1 (en) | 2003-12-12 |
AU2003231801A8 (en) | 2003-12-12 |
TW200404539A (en) | 2004-04-01 |
MXPA04011621A (es) | 2005-03-31 |
CA2486564A1 (fr) | 2003-12-04 |
JP2005531571A (ja) | 2005-10-20 |
BR0306625A (pt) | 2006-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7528134B2 (en) | Acetamides and benzamides that are useful in treating sexual dysfunction | |
KR102438302B1 (ko) | 리신 특이적 데메틸라제-1의 억제제 | |
AU2004253649B2 (en) | Thiazolylpiperidine derivatives as MTP inhibitors | |
KR100970294B1 (ko) | 복소환 화합물 | |
EP2456440B1 (fr) | Inhibiteurs de quinoléinone pde2 | |
US20090069340A1 (en) | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | |
US20040029887A1 (en) | Acetamides and benzamides that are useful in treating sexual dysfunction | |
EP1351936A1 (fr) | Derives aryle de piperidine et de piperazine comme inducteurs de l'expression du recepteur ldl | |
CA2650914A1 (fr) | E ex as een es a s e y s u o y o rea as o ows : composes agonistes des recepteurs muscariniques qui peuvent etre efficaces pour traiter la douleur, la maladie d'alzheimer et/ou la schizophrenie | |
AU2005267930A1 (en) | Novel piperidine derivative for the treatment of depression | |
TW201028408A (en) | Compounds | |
JP2009520791A (ja) | 酵素阻害剤 | |
AU2002303128B2 (en) | Benzimidazoles that are useful in treating sexual dysfunction | |
CA2538381A1 (fr) | Nouveaux composes | |
US20070265249A1 (en) | Fused Bicyclic Aromatic Compounds that are Useful in Treating Sexual Dysfunction | |
MX2014015691A (es) | Derivados de 1- [m-carboxamido (hetero) aril-metil]-heterociclil-c arboxamida. | |
US20060009461A1 (en) | Acetamides and benzamides that are useful in treating sexual dysfunction | |
AU2002303128A1 (en) | Benzimidazoles that are useful in treating sexual dysfunction | |
US20070105893A1 (en) | Novel Compounds | |
WO2003076431A1 (fr) | Derives de benzimidazole utilises pour traiter un dysfonctionnement sexuel | |
EP1509213A2 (fr) | Acetamides et benzamides utilises dans le traitement d'une dysfonction sexuelle | |
US20030232836A1 (en) | Acetamides and benzamides that are useful in treating sexual dysfunction | |
US20040110766A1 (en) | Benzimidazoles that are useful in treating sexual dysfunction | |
CA2172163A1 (fr) | Derives d'imidazolidinone; leur sels d'addition avec un acide et remede pour la demence senile | |
US20040002488A1 (en) | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20041221 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1074781 Country of ref document: HK |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ZHANG, HENRY, Q. Inventor name: XIA, ZHIREN Inventor name: WANG, XUEQING Inventor name: STEWART, ANDREW, O. Inventor name: PATEL, MEENA, V. Inventor name: MORTELL, KATHLEEN, H. Inventor name: MATULENKO, MARK, A. Inventor name: KOLASA, TEODOZYJ Inventor name: HAKEEM, AHMED, A. Inventor name: DAANEN, JEROME, F. Inventor name: BHATIA, PRAMILA, A. |
|
17Q | First examination report despatched |
Effective date: 20070221 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20100323 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1074781 Country of ref document: HK |